Glycophospholipid polymer network and uses thereof

Abstract

A glycophospholipid polymer is disclosed. This glycophospholipid polymer comprises a reaction product of one or more glycosaminoglycans and one or more phospholipids. A glycophospholipid polymer network comprising a reaction product of one or more glycosaminoglycans, one or more phospholipids, and one or more crosslinking agents is also disclosed.

Description

[Technical field]

[0001] The present invention relates generally to glycophospholipid polymer networks and uses thereof. [Background technology]

[0002] It is highly desirable for contact lenses to be as comfortable as possible for the wearer. Contact lens manufacturers are constantly working to improve lens comfort. Nevertheless, many contact lens wearers still experience dryness or eye irritation throughout the day, especially toward the end of the day. Lenses that are not sufficiently wet at any point in time cause significant discomfort to the lens wearer. Wetting eye drops can be used as needed to alleviate such discomfort, but it would certainly be preferable if such discomfort did not occur in the first place.

[0003] Glycosaminoglycans (GAGs) are a group of polysaccharides composed of repeating disaccharide units. Due to their high polarity and water affinity, they can be found in many systems in the human body. For example, GAGs are present on the surface of cells and in the extracellular matrix of animals (e.g., skin, cartilage, lung).

[0004] Each GAG has a chemical structure that contains a repeating basic disaccharide structure consisting of uronic acid and hexosamine, and is optionally sulfated to various degrees. GAGs are mainly classified into three groups according to the type of disaccharide that constitutes them: the first group of compounds consisting of chondroitin sulfate or dermatan sulfate, the second group of compounds consisting of heparan sulfate or heparin, and the third group of compounds consisting of hyaluronic acid. For example, compounds consisting of chondroitin sulfate or dermatan sulfate consist of a disaccharide: uronic acid (glucuronic acid or iduronic acid) (β1→3) N-acetylgalactosamine, compounds consisting of heparan sulfate or heparin consist of a disaccharide: uronic acid (glucuronic acid or iduronic acid) (β1→4) N-acetylglucosamine, and hyaluronic acid consists of a disaccharide: glucuronic acid (β1→3) N-acetylglucosamine. In addition, the structures are very diverse due to the combination with modifications by sulfation.

[0005] These GAGs are known as biological materials that possess both physicochemical properties derived from their characteristic viscoelasticity and biological properties mediated by interactions with various functional proteins, depending on their molecular size and sulfation pattern.

[0006] Methacryloylethyl phosphorylcholine (MPC) polymers are known to resist both protein adsorption and cell adhesion and are widely used to construct non-biofouling surfaces in various biomedical applications where a high level of biocompatibility is required (e.g., coatings that significantly reduce adhesion of common infectious bacteria). MPC units generally contain zwitterionic phospholipid groups (i.e., phosphorylcholine (PC)). PC is also present in cell membranes and, due to its high biocompatibility, has non-thrombogenic properties that minimize clot formation and protein fouling. PC has both positive and negative charges but is overall electrically neutral, and is highly polar and has a high affinity for water, which makes PC materials less sticky.

[0007] It would be desirable to provide improved GAGs that can make biomedical devices such as contact lenses as comfortable as possible for the wearer and exhibit suitable physical and chemical properties, such as lubricity and wettability. Summary of the Invention

[0008] According to one exemplary embodiment, a glycophospholipid polymer is provided that comprises the reaction product of one or more glycosaminoglycans and one or more phospholipids.

[0009] According to a second exemplary embodiment, a cross-linked glycophospholipid polymer network is provided that includes one or more glycosaminoglycans cross-linked with one or more phospholipids.

[0010] According to a third exemplary embodiment, a cross-linked glycophospholipid polymer network is provided that comprises the reaction product of one or more glycosaminoglycans, one or more phospholipids, and one or more cross-linking agents.

[0011] According to a fourth exemplary embodiment, there is provided a biomedical device having a coating on a surface thereof, the coating comprising one or more glycophospholipid polymers comprising the reaction product of one or more glycosaminoglycans and one or more phospholipids.

[0012] According to a fifth exemplary embodiment, there is provided a packaging system for storage of ophthalmic devices, the packaging system comprising a sealed container housing one or more unused ophthalmic devices immersed in an aqueous packaging solution comprising one or more glycophospholipid polymers comprising reaction products of one or more glycosaminoglycans and one or more phospholipids, the solution having an osmolality of at least about 200 mOsm / kg and a pH of about 6 to about 9, and being sterile.

[0013] According to a sixth exemplary embodiment, there is provided a method for preparing a package containing a storable sterile ophthalmic device, the method comprising: (a) immersing the ophthalmic device in an aqueous packaging solution comprising one or more glycophospholipid polymers comprising reaction products of one or more glycosaminoglycans and one or more phospholipids, the solution having an osmolality of at least about 200 mOsm / kg and a pH in the range of about 6 to about 9; (b) packaging the solution and the device in a manner that prevents contamination of the device with microorganisms; and (c) sterilizing the packaged solution and the device.

[0014] According to a seventh exemplary embodiment, there is provided an aqueous ophthalmic composition comprising one or more glycophospholipid polymers comprising reaction products of one or more glycosaminoglycans and one or more phospholipids, the aqueous ophthalmic composition having an osmolality in the range of about 200 mOsmol / kg to about 400 mOsmol / kg.

[0015] According to an eighth exemplary embodiment, there is provided a gel composition for promoting wound healing, the gel composition comprising one or more glycophospholipid polymers comprising reaction products of one or more glycosaminoglycans and one or more phospholipids.

[0016] According to a ninth exemplary embodiment, there is provided a wound dressing comprising a gel composition comprising one or more glycophospholipid polymers comprising reaction products of one or more glycosaminoglycans and one or more phospholipids.

[0017] The glycophospholipid polymers and cross-linked glycophospholipid polymer networks of the present invention are believed to advantageously exhibit enzymatic, oxidative, and thermal degradation, and thus exhibit higher stability, longer shelf life, and desired conformational rigidity.In addition, the glycophospholipid polymers and cross-linked glycophospholipid polymer networks of the present invention are believed to exhibit favorable physical and chemical properties, such as oxygen permeability, lubricity, mucoadhesiveness, and wettability.The glycophospholipid polymers and cross-linked glycophospholipid polymer networks of the present invention are further believed to advantageously exhibit antimicrobial activity upon sustained contact with the body, by reacting one or more glycosaminoglycans with one or more phospholipids and optionally one or more cross-linking agents.

[0018] The glycophospholipid polymers and cross-linked glycophospholipid polymer networks of the present invention can advantageously improve the lubricity of the surface of biomedical devices such as contact lenses. For example, the benefits of improving lubricity using the glycophospholipid polymers and cross-linked glycophospholipid polymer networks of the present invention include, for example, minimizing the interaction between the contact lens and its respective packaging blister, robustening the lens surface against processing and handling conditions, and improving comfort when inserted into a subject's eye, as well as reducing deposits (e.g., proteins, lipids, etc.) and thus reducing the likelihood of a contact lens wearer forming a biofilm on the lens surface.

[0019] In addition, the glycophospholipid polymers and cross-linked glycophospholipid polymer networks of the present invention advantageously improve the wettability of the surface of biomedical devices such as contact lenses. The benefits of improved wettability using the glycophospholipid polymers and cross-linked glycophospholipid polymer networks of the present invention are believed to include, for example, effects such as coating and moisturizing properties on the ocular surface, slowing the evaporation of the aqueous layer of the device and potentially alleviating dry eye symptoms. The present invention and its preferred embodiments will be described below, although they overlap with other descriptions. However, the present invention is not limited to the following. [1] A glycophospholipid polymer comprising the reaction product of one or more glycosaminoglycans, one or more phospholipids, and a first crosslinker. [2] The glycophospholipid polymer according to [1], wherein the one or more glycosaminoglycans are selected from the group consisting of chondroitin, chondroitin sulfate, dermatan, dermatan sulfate, heparin, heparan sulfate, hyaluronan, hyaluronic acid, sucrose, lactulose, lactose, maltose, trehalose, cellobiose, mannobiose, and chitobiose. [3] The glycophospholipid polymer according to [1] or [2], wherein the one or more phospholipids are selected from the group consisting of phosphorylcholine, phosphorylhistidine, phosphorylproline, phosphorylserine, α-phosphatidylcholine, α-phosphatidylethanolamine, α-phosphatidyl-L-serine, α-phosphatidylinositol, α-phosphatidic acid, α-phosphatidyl-DL-glycerol, α-lysophosphatidylcholine, sphingomyelin, and cardiolipin. [4] The glycophospholipid polymer according to any one of [1] to [3], wherein the one or more glycosaminoglycans are hyaluronic acid, and the one or more phospholipids contain phosphorylcholine. [5] The glycophospholipid polymer according to any one of [1] to [4], wherein the one or more phospholipids are phosphorylcholine-containing phospholipids represented by the following structure: [C1] [In the formula, n is an integer of 1 to 5, and R', R'', and R''' each independently represent C 1 ~C 8 Alkyl group, C 1 ~C 8 a hydroxyalkyl group, or a heteroatom-containing group. [6] 5. The reaction product of claim 4, About 0.01 to about 50 wt. % of said one or more glycosaminoglycans, based on the total weight of the reaction product; and About 0.01 to about 50 wt. % of said one or more phospholipids based on the total weight of the reaction product. The glycophospholipid polymer network according to any one of [1] to [5], [7] The glycophospholipid polymer according to any one of [1] to [6], wherein the one or more first crosslinkers include a bifunctional or polyfunctional crosslinker having two or more functional groups capable of reacting with functional groups of the one or more glycosaminoglycans and the one or more phospholipids. [8] The one or more first crosslinkers may be 1,4-butanediol diglycidyl ether, 1,2-bis(2,3-epoxypropoxy)ethylene, ethylene glycol diglycidyl ether, 1,2-ethanediol diglycidyl ether, diepoxyoctane, 1,6-hexanediol diglycidyl ether, polypropylene glycol diglycidyl ether, polytetramethylene glycol diglycidyl ether, neopentyl glycol diglycidyl ether, polyglycerol polyglycidyl ester, diglycidyl ether, ... The glycophospholipid polymer according to any one of [1] to [6], comprising a bifunctional or polyfunctional crosslinker comprising a bis- or polyfunctional crosslinker selected from the group consisting of glycerol polyglycidyl ether, glycerol polyglycidyl ether, trimethylolpropane polyglycidyl ether, pentaerythritol polyglycidyl ether, sorbitol polyglycidyl ether, 1,2,7,8-diepoxyoctane, 1,3-butadiene diepoxide, pentaerythritol tetraglycidyl ether, and polyepoxide. [9] The glycophospholipid polymer according to [1] to [6], wherein the one or more first crosslinkers comprise a dihydrazide crosslinker selected from the group consisting of succinic acid dihydrazide, glutaric acid dihydrazide, adipic acid dihydrazide, pimelic acid dihydrazide, suberic acid dihydrazide, azelaic acid dihydrazide, sebacic acid dihydrazide, undecanedioic acid dihydrazide, dodecanedioic acid dihydrazide, brassylic acid dihydrazide, tetradecanedioic acid dihydrazide, pentadecanedioic acid dihydrazide, thapsic acid dihydrazide, and octadecanedioic acid dihydrazide.

[10] The glycophospholipid polymer according to any one of [1] to [6], wherein the one or more first crosslinkers include a dihydric alcohol crosslinker selected from the group consisting of ethylene glycol, propylene glycol, butylene glycol, diethylene glycol, dipropylene glycol, neopentyl glycol, 1,3-propanediol, hexylene glycol, pentylene glycol, heptylene glycol, and octylene glycol.

[11] The glycophospholipid polymer according to any one of [1] to [6], wherein the one or more first crosslinkers include a polyhydric alcohol crosslinker selected from the group consisting of glycerin, pentaerythritol, xylitol, and galactitol.

[12] The one or more first crosslinkers have the formula XN=C=NX, where each X is independently a C optionally substituted with 1-2 dialkylamino groups. 1 ~C 6 Alkyl, or C 5 ~C 6 The glycophospholipid polymer according to any one of [1] to [6], comprising a carbodiimide crosslinker, wherein the carbodiimide crosslinker is a cycloalkyl group.

[13] The glycophospholipid polymer according to [1] to [6], wherein the one or more first crosslinkers are selected from the group consisting of methacrylic anhydride, octenylsuccinic anhydride, formaldehyde, gluteraldehyde, gluraraldehyde, acid chlorides, n-hydroxysuccinimide, polyethylene glycol diacrylate, polyethylene glycol diamine, divinyl sulfone, urea, and diisocyanate.

[14] The glycophospholipid polymer according to any one of [1] to [6], wherein one or more additional glycosaminoglycans are crosslinked with a reaction product with one or more second crosslinkers.

[15] The glycophospholipid polymer according to

[14] , wherein the one or more second crosslinkers are the same as the first crosslinker.

[16] The glycophospholipid polymer according to

[14] , wherein the one or more second crosslinkers are different from the first crosslinker.

[17] 5. The reaction product of claim 4, About 0.01 to about 50 wt. % of said one or more glycosaminoglycans, based on the total weight of the reaction product; About 0.01 to about 50 wt. % of the one or more phospholipids, based on the total weight of the reaction product; and % of one or more first crosslinking agents, based on the total weight of the reaction product. The glycophospholipid polymer according to any one of [1] to

[16] ,

[18] 5. The reaction product of claim 4, About 0.1 to about 5 wt. % of said one or more glycosaminoglycans, based on the total weight of the reaction product; About 0.1 to about 5 wt. % of the one or more phospholipids, based on the total weight of the reaction product; and From about 0.05 to about 10 wt. %, based on the total weight of the reaction product, of one or more crosslinking agents The glycophospholipid polymer according to any one of [1] to

[16] ,

[19] The glycophospholipid polymer according to any one of [1] to

[13] , wherein the reaction product comprises the one or more glycosaminoglycans crosslinked with the one or more first crosslinkers and the one or more phospholipids.

[20] The glycophospholipid polymer according to

[19] , wherein the crosslinked reaction product has a weight-average molecular weight in the range of about 20,000 to about 6,000,000 Da.

[21] A biomedical device having a coating on a surface thereof, the coating comprising one or more of the glycophospholipid polymers described in [1] to

[20] .

[22] 21. The biomedical device according to claim 20, wherein the biomedical device is an ophthalmic lens.

[23] The biomedical device described in

[22] , wherein the ophthalmic lens is a contact lens or an intraocular lens.

[24] A packaging system for storing an ophthalmic device, comprising a sealed container housing one or more unused ophthalmic devices immersed in an aqueous packaging solution containing one or more of the glycophospholipid polymers described in [1] to

[20] , the solution having an osmolality of at least about 200 mOsm / kg and a pH of about 6 to about 9, and being sterilized.

[25] 24. The packaging system of claim 23, wherein the one or more unused ophthalmic devices are contact lenses.

[26] 1. A method for preparing a package containing a storable sterile ophthalmic device, comprising: (a) immersing an ophthalmic device in an aqueous packaging solution containing one or more of the glycophospholipid polymers described in [1] to

[20] , the solution having an osmolality of at least about 200 mOsm / kg and a pH in the range of about 6 to about 9; (b) packaging the solution and the device in a manner that prevents contamination of the device with microorganisms; (c) sterilizing the packaged solution and device; A method comprising:

[27] The method according to

[26] , wherein the ophthalmic device is a contact lens.

[28] An aqueous ophthalmic composition comprising one or more of the glycophospholipid polymers described in [1] to

[20] and having an osmolality in the range of about 200 mOsmol / kg to about 400 mOsmol / kg.

[29] The aqueous ophthalmic composition according to

[28] , which is in the form of an eye care or contact lens care product selected from the group consisting of eye drops, contact lens storage solution, contact lens cleaning solution, and multi-purpose contact lens solution.

[30] The aqueous ophthalmic composition according to

[28] , which is in the form of a multipurpose solution or rewetting eye drops.

[31] 1. A gel composition for promoting wound healing, comprising one or more glycophospholipid polymers comprising a reaction product of one or more glycosaminoglycans and one or more phospholipids.

[32] A wound dressing comprising the gel composition according to

[31] . DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0020] Exemplary embodiments described herein are directed to glycophospholipid polymers and crosslinked glycophospholipid polymer networks useful for treating the surfaces of biomedical devices intended for direct contact with bodily tissues or fluids. Generally, the glycophospholipid polymers include the reaction product of one or more glycosaminoglycans (GAGs) with one or more phospholipids. A GAG is a molecule with many alternating subunits. Generally, the GAG ​​can be any natural or synthetic polymer containing uronic acid represented by the formula ABABAB, where A is a uronic acid and B is an amino sugar that is either O- or N-sulfated, and the A and B units may be heterogeneous in terms of epimer content or sulfation. Other GAGs are sulfated with different sugars. There are many different types of GAGs with commonly understood structures, such as chondroitin sulfate, dermatan, heparan, heparin, dermatan sulfate, hyaluronic acid or its salts (e.g., sodium or potassium hyaluronate), heparan sulfate, as well as other disaccharides such as sucrose, lactulose, lactose, maltose, trehalose, cellobiose, mannobiose, and chitobiose. Glycosaminoglycans can be purchased from Sigma and many other biochemical suppliers.

[0021] In one exemplary embodiment, the GAG ​​is hyaluronic acid or its salt. Hyaluronic acid is a well-known natural water-soluble biodegradable polymer consisting of two alternating linked sugars, D-glucuronic acid, and N-acetylglucosamine, linked through alternating β-(1,4) and β-(1,3) glycosidic bonds. Hyaluronic acid is a non-sulfated GAG. Hyaluronan. The polymer is hydrophilic and highly viscous in aqueous solution at relatively low solute concentrations. It often occurs naturally as the sodium salt, sodium hyaluronate. Methods for preparing commercial hyaluronan and its salts are well known. Hyaluronan can be purchased from Seikagaku Company, Clear Solutions Biotech, Inc., Pharmacia Inc., Sigma Inc., and many other suppliers. Hyaluronic acid has one or more repeating units of the structure represented by the following formula: [ka] Thus, the repeating units in hyaluronic acid may be as follows: [ka]

[0022] Generally, hyaluronic acid or its salts can have from about 2 to about 1,500,000 disaccharide units. In one embodiment, the weight average molecular weight of the hyaluronic acid or salt thereof can range from about 10,000 to about 3,000,000 Daltons (Da), with a lower limit of about 10,000, about 20,000, about 30,000, about 40,000, about 50,000, about 60,000, about 70,000, about 80,000, about 90,000, or about 100,000, and an upper limit of up to about 200,000, about 300,000, about 400,000, about 500,000, about 600,000, about 700,000, about 800,000, about 900,000, about 1,000,000, or about 2,800,000, and any lower limit may be combined with any upper limit.

[0023] In one exemplary embodiment, the GAG ​​is chondroitin sulfate. Generally, chondroitin sulfate is a linear sulfated polysaccharide in which repeating units of β-D-glucuronic acid (GlcA) and N-acetyl-β-D-galactosamine (GalNAc) are arranged in a GlcA-β(1,3)-GalNAc-β(1,4) glycosidic bond. In one embodiment, chondroitin sulfate has one or more repeating units of the structure represented by the following formula: [ka]

[0024] In one exemplary embodiment, chondroitin sulfate has one or more repeat units of a structure represented by the following formula: [ka]

[0025] In general, chondroitin sulfate can have from about 2 to about 1,500,000 repeating units. In one embodiment, the weight average molecular weight of chondroitin sulfate can range from about 10,000 to about 3,000,000 Da, with the lower limit being about 5,000, 10,000, about 20,000, about 30,000, about 40,000, about 50,000, about 60,000, about 70,000, about 80,000, about 90,000, or about 100,000. 00 to an upper limit up to about 200,000, about 300,000, about 400,000, about 500,000, about 600,000, about 700,000, about 800,000, about 900,000, about 1,000,000, or about 3,000,000, and any lower limit may be combined with any upper limit, and any upper limit may be combined with any upper limit.

[0026] Suitable phospholipids for reacting with one or more GAGs include, for example, phosphorylcholine, phosphorylhistidine, phosphorylproline, phosphorylserine, α-phosphatidylcholine, α-phosphatidylethanolamine, α-phosphatidyl-L-serine, α-phosphatidylinositol, α-phosphatidic acid, α-phosphatidyl-DL-glycerol, α-lysophosphatidylcholine, sn-glycero-3-phosphatidylcholine (GPC) derived from soy phosphatidylcholine sphingomyelin (choline alphoscerate), and cardiolipin. The phospholipids described herein are commercially available or can be prepared by techniques well known in the art (see, for example, Park et al., "Facile Syntheses of L-α-Glycerophosphorylcholine", Bull. Korean Chem. Soc. 2010, Vol. 31, No. pp. 9 2689-2691).

[0027] In one embodiment, the phosphorylcholine-containing phospholipid comprises a zwitterionic group as follows: [ka] [wherein n is an integer from 1 to 5, and R', R'', and R''' are, independently of one another, a C1-C8 alkyl group, a C1-C8 hydroxyalkyl group, or a heteroatom-containing group (e.g., histidine and proline). As will be readily understood by one of skill in the art, the phosphorylcholine-containing phospholipids described above further comprise one or more reactive groups capable of reacting with one or more GAGs and one or more crosslinkers described hereinafter, such as hydroxyl-containing groups, epoxide-containing groups, amine-containing groups, aldehyde-containing groups, thiol-containing groups, carboxylic acid-containing groups, cyano-containing groups, halogen-containing groups, and the like. Representative examples of suitable phosphorylcholine phospholipids having the zwitterionic groups described above include, but are not limited to, glyceryl phosphorylcholine, ethanaminium, 2·[[hydroxy·2·oxiranylmethoxy]phosphinyl)oxy)·N,N,N·trimethyl, inner salt, and hydroxyethyl phosphorylcholine.

[0028] The term "hydroxyl-containing group" should be understood to mean any group that contains a hydroxyl moiety. Representative examples of hydroxyl-containing groups for use herein include a hydroxyl group that is directly attached to the remainder of the molecule, i.e., -OH, or one or more hydroxyl-containing groups that are attached to the remainder of the molecule via a linking group, such as an alkyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, aryl, or arylalkyl group.

[0029] The term "epoxide-containing group" should be understood to mean any group that contains an epoxide moiety. Representative examples of epoxide-containing groups for use herein include alkylene oxides, especially lower alkylene oxides, such as ethylene oxide, propylene oxide, butylene oxide, alcohol epoxides, such as glycidol, and epihalohydrins, such as epichlorohydrin, epibromohydrin, epiiodohydrin, 1,2-epoxy-4-chlorobutane, 1,2-epoxy-4-bromobutane, 1,2-epoxy-4-iodobutane, 2,3 ... 4-chlorobutane, 2,3-epoxy-4-bromobutane, 2,3-epoxy-4-iodobutane, 2,3-epoxy-5-chloropentane, 2,3-epoxy-5-bromopentane, 1,2-epoxy-5-chloropentane, and epoxy compounds such as 2,2-bis(p-1,2-epoxypropoxyphenyl)-propane, 1,4-bis(1,2-epoxypropoxy)benzene, and N,N'-bis(2,3-epoxypropyl)piperazine.

[0030] The term "amine-containing group" should be understood to mean any group that contains an amine moiety. Representative examples of amine-containing groups for use herein include alkyl or aryl amine groups, such as those of the general formula -R 1 NR 2 R 3 where R 1 is C2~C 30 alkylene, arylene, or cycloalkylene; R 2 and R 3 are C1~C independently 30 Examples include hydrocarbon groups, such as alkyl groups, aryl groups, or cycloalkyl groups as defined herein.

[0031] The term "aldehyde-containing group" should be understood to mean any group that contains an aldehyde moiety. Representative examples of aldehyde-containing groups for use herein include an aldehyde group that is directly bonded to the remainder of the molecule, i.e., -CHO, or one or more aldehyde groups that are bonded to the remainder of the molecule via a linking group, such as an alkylene, cycloalkyl, cycloalkylalkylene, cycloalkenyl, aryl, or arylalkylene group.

[0032] The term "thiol-containing group" should be understood to mean any group that contains a thiol moiety. Representative examples of thiol-containing groups for use herein include a thiol group that is directly bonded to the remainder of the molecule, i.e., -SH, or one or more thiol groups that are bonded to the remainder of the molecule via a linking group, such as an alkylene, cycloalkyl, cycloalkylalkylene, cycloalkenyl, aryl, or arylalkylene group.

[0033] The term "carboxylic acid-containing group" should be understood to mean any group that contains a carboxylic acid moiety. Representative examples of carboxylic acid-containing groups for use herein include a carboxylic acid group that is directly attached to the remainder of the molecule, i.e., -COOH, or one or more carboxylic acid groups that are attached to the remainder of the molecule via a linking group, such as an alkylene, cycloalkyl, cycloalkylalkylene, cycloalkenyl, aryl, or arylalkylene group.

[0034] The term "cyano-containing group" should be understood to mean any group that contains a cyano moiety. Representative examples of cyano-containing groups for use herein include a cyano group that is directly bonded to the remainder of the molecule, i.e., -CN, or one or more cyano groups that are bonded to the remainder of the molecule via a linking group, such as an alkylene, cycloalkyl, cycloalkylalkylene, cycloalkenyl, aryl, or arylalkylene group.

[0035] The term "halogen-containing group" should be understood to mean any group that contains a halogen moiety. Representative examples of halogen-containing groups for use herein include a halogen group (i.e., F, Cl, B, I, etc.) directly bonded to the remainder of the molecule, or one or more halogen groups bonded to the remainder of the molecule via a linking group (e.g., an alkylene, cycloalkyl, cycloalkylalkylene, cycloalkenyl, aryl, or arylalkylene group, etc.).

[0036] Representative examples of alkyl groups for use herein include straight or branched hydrocarbon chain radicals containing carbon and hydrogen atoms of from 1 to about 18 carbon atoms, with or without unsaturation to the remainder of the molecule, such as, for example, methyl, ethyl, n-propyl, 1-methylethyl (isopropyl), n-butyl, n-pentyl, and the like.

[0037] Representative examples of alkylene groups for use herein include straight or branched alkyl chain radicals containing carbon and hydrogen atoms of from 1 to about 30 carbon atoms, or from 1 to about 6 carbon atoms, with or without unsaturation to the remainder of the molecule, e.g., methylene, ethylene, and the like.

[0038] Representative examples of cycloalkyl groups for use herein include substituted or unsubstituted non-aromatic monocyclic or polycyclic ring systems of about 3 to about 18 carbon atoms, such as, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, perhydronaphthyl, adamantyl, and norbornyl groups, bridged cyclic or spiro bicyclic groups (e.g., spiro-(4,4)-non-2-yl, and the like), which may optionally contain one or more heteroatoms (e.g., O, N, and the like).

[0039] Representative examples of cycloalkylalkyl groups for use herein include substituted or unsubstituted cyclic ring-containing radicals containing from about 3 to about 18 carbon atoms directly bonded to an alkyl group and attached to the main structure of the monomer at any carbon from the alkyl group, thereby creating a stable structure, such as, for example, cyclopropylmethyl, cyclobutylethyl, cyclopentylethyl, and the like, where the cyclic ring may optionally contain one or more heteroatoms (e.g., O, N, etc.).

[0040] Representative examples of cycloalkenyl groups for use herein include substituted or unsubstituted cyclic ring-containing radicals having at least one carbon-carbon double bond and containing from about 3 to about 18 carbon atoms, such as, for example, cyclopropenyl, cyclobutenyl, cyclopentenyl, and the like, where the cyclic ring optionally contains one or more heteroatoms (e.g., O, N, and the like).

[0041] Representative examples of aryl groups for use herein include substituted or unsubstituted monoaromatic or polyaromatic radicals containing from about 5 to about 25 carbon atoms, such as, for example, phenyl, naphthyl, tetrahydronaphthyl, indenyl, biphenyl, and the like, and optionally containing one or more heteroatoms (e.g., O, N, and the like).

[0042] Representative examples of arylalkylene groups for use herein include substituted or unsubstituted aryl groups as defined above directly bonded to an alkylene group as defined above, such as, for example, -CH2C6H5, -C2H5C6H5, and the like, where the aryl group may optionally contain one or more heteroatoms (such as, for example, O and N).

[0043] Phospholipids for use herein are commercially available or can be prepared by methods known in the art. For example, ethanaminium, 2·[[hydroxy-2-oxiranylmethoxy]phosphinyl)oxy)-N,N,N·trimethyl inner salt can be prepared according to the method described in Example 11 of J.Org.Chemistry, 67194-199 (2002), or according to the method described in U.S. Patent No. 7,674,782, the contents of which are incorporated herein by reference. In addition, hydroxyethyl phosphorylcholine can be prepared according to Journal of the American Chemical Society, 130(23), 7357-7363 (2008), the contents of which are incorporated herein by reference. Also commercially available from Shanghai Chemhere Co., Ltd. (Shanghai, Hong Kong).

[0044] In one exemplary embodiment, the reaction product of one or more GAGs and one or more phospholipids includes one or more crosslinkers, for example, to crosslink one or more GAGs with one or more phospholipids to form a crosslinked glycophospholipid polymer network. The crosslinker for use herein can be any suitable crosslinker known in the art. In general, suitable crosslinkers are, for example, crosslinkers that have functional groups complementary to one or more GAGs and one or more phospholipids. In one embodiment, suitable crosslinkers include, for example, bifunctional or multifunctional crosslinkers. The bifunctional or multifunctional crosslinker connects one or more GAGs to one or more phospholipids. In addition, the bifunctional or multifunctional crosslinker further acts as a spacer between one or more GAGs and one or more phospholipids. In general, the bifunctional or multifunctional crosslinker includes two or more functional groups that can react with functional groups of one or more GAGs (e.g., hyaluronic acid and one or more phospholipids) to form a covalent bond.

[0045] Suitable bifunctional or polyfunctional crosslinking agents include, for example, divinylsulfone, diepoxide, multiepoxide, dihydrazide, dihydric alcohol, polyhydric alcohol, polyhydric thiol, anhydride, carbodiimide, polycarboxylic acid, carboxymethylthiol, cysteine, and cysteine-like amino acid. In one embodiment, the bifunctional or polyfunctional crosslinking agent is a bis-epoxide or polyepoxide (e.g., diglycidyl ether derivative). According to one embodiment, the bifunctional or polyfunctional epoxide crosslinking agent contains two or more glycidyl ether functional groups. The glycidyl ether functional groups react with the primary hydroxyl groups of hyaluronic acid or chondroitin sulfate to form ether bonds. In one embodiment, suitable bis- or polyfunctional crosslinkers include, for example, 1,4-butanediol diglycidyl ether (BDDE), 1,2-bis(2,3-epoxypropoxy)ethylene (EGDGE), ethylene glycol diglycidyl ether (EGDE), 1,2-ethanediol diglycidyl ether (EDDE), diepoxyoctane, 1,6-hexanediol diglycidyl ether, polypropylene glycol diglycidyl ether, polytetramethylene glycol diglycidyl ether, neopentyl glycol diglycidyl ether, polyglycerol polyglycidyl ester, diglycerol polyglycidyl ether, glycerol polyglycidyl ether, trimethylolpropane polyglycidyl ether, pentaerythritol polyglycidyl ether, sorbitol polyglycidyl ether, 1,2,7,8-diepoxyoctane, 1,3-butadiene diepoxide, pentaerythritol tetraglycidyl ether, polyepoxides, and the like.

[0046] Suitable dihydrazide crosslinkers include, for example, succinic acid dihydrazide, glutaric acid dihydrazide, adipic acid dihydrazide, pimelic acid dihydrazide, suberic acid dihydrazide, azelaic acid dihydrazide, sebacic acid dihydrazide, undecanedioic acid dihydrazide, dodecanedioic acid dihydrazide, brassylic acid dihydrazide, tetradecanedioic acid dihydrazide, pentadecanedioic acid dihydrazide, thapsic acid dihydrazide, octadecanedioic acid dihydrazide, and the like.

[0047] Suitable dihydric alcohol crosslinkers include, for example, ethylene glycol, propylene glycol, butylene glycol diethylene glycol, dipropylene glycol, neopentyl glycol, 1,3-propanediol, hexylene glycol, pentylene glycol, heptylene glycol, octylene glycol, etc. Suitable polyhydric alcohol crosslinkers include, for example, glycerin, pentaerythritol, xylitol, galactitol, etc. Suitable carbodiimide crosslinkers include, for example, compounds of the formula XN=C=NX, where each X is independently a C1-C6 alkyl optionally substituted with 1-2 dialkylamino groups, or C5-C6 cycloalkyl groups (e.g., 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and cyclohexylcarbodiimide). Suitable anhydride crosslinkers include, for example, methacrylic anhydride, octenylsuccinic anhydride, etc. In one embodiment, suitable crosslinkers are aldehyde crosslinkers, such as formaldehyde, glutaraldehyde, glutaraldehyde, etc. In one embodiment, suitable crosslinkers include, for example, acid chlorides, n-hydroxysuccinimide, polyethylene glycol diacrylates, polyethylene glycol diamines, urea, diisocyanates, etc.

[0048] The glycophospholipid polymer network of the present invention can be obtained by forming a solution of one or more GAGs and one or more phospholipids, and optionally adding one or more crosslinking agents to form a crosslinked polymer network. The solution is stirred for a suitable time sufficient to react and / or crosslink the one or more GAGs and one or more phospholipids. In one embodiment, the reaction between the one or more GAGs and one or more phospholipids can occur at between 1° C. and about 99° C. for a period of about 2 hours to about 36 hours.

[0049] The solution can include one or more suitable solvents, such as water, crown ethers, dimethylsulfoxide (DMSO), dimethylformamide (DMF), and other aprotic solvents.

[0050] Generally, the amount of one or more GAGs in the solution can range from about 0.010 to about 50 wt.% based on the total weight of the solution. In one exemplary embodiment, the amount of one or more GAGs in the solution can range from about 0.1 to about 5 wt.% based on the total weight of the solution. In one exemplary embodiment, the amount of one or more phospholipids in the solution can range from about 0.01 to about 50 wt.% based on the total weight of the solution. In one exemplary embodiment, the amount of one or more phospholipids in the solution can range from about 0.1 to about 5 wt.% based on the total weight of the solution. The crosslinker can be added to the solution in an amount ranging from about 0.05 to about 20 wt.% based on the total weight of the solution.

[0051] Those skilled in the art will readily understand and appreciate that the reaction product constitutes a complex mixture of compounds. For example, the reaction product of one or more GAGs, one or more phospholipids, and one or more crosslinkers may include, for example, a polymer resulting from the reaction of one or more GAGs with one or more phospholipids, a GAG crosslinked with a phospholipid, a GAG crosslinked with a GAG, a phospholipid crosslinked with a phospholipid, an unreacted GAG, and an unreacted phospholipid. In one exemplary embodiment, the weight average molecular weight of the GAG ​​crosslinked with a phospholipid may range from about 20,000 to about 6,000,000 Da, with a lower limit of about 20,000, about 30,000, about 40,000, about 50,000, about 60,000, about 70,000, about 80,000, about 90,000, or about 100,000 Da, and an upper limit of up to about 200,000 Da. 0, about 300,000, about 400,000, about 500,000, about 600,000, about 700,000, about 800,000, about 900,000, about 1,000,000, about 2,000,000, about 3,000,000, about 4,000,000, about 5,000,000, or up to about 6,000,000 Da, and any lower limit may be combined with any upper limit. It is not necessary to isolate one or more particular components of the reaction product mixture. In fact, the reaction product mixture can be used as is.

[0052] In another exemplary embodiment, a biomedical device is provided comprising the glycophospholipid polymer and / or cross-linked glycophospholipid polymer network of the present invention on its surface. The glycophospholipid polymer and / or cross-linked glycophospholipid polymer network may be provided on the entire surface of the biomedical device or on a portion of the surface of the biomedical device. The glycophospholipid polymer and / or cross-linked glycophospholipid polymer network may also be provided within the construct of the biomedical device. As used herein, the term "biomedical device" is understood to mean any article designed to be used in or on mammalian tissue or fluid, preferably human tissue or fluid. Representative examples of biomedical devices include, but are not limited to, applications for artificial ureters, diaphragms, intrauterine devices, heart valves, catheters, denture liners, prosthetic devices, and ophthalmic lenses, the latter intended for placement in or directly on the eye, such as intraocular devices and contact lenses. In one embodiment, the biomedical device is an ophthalmic device, particularly a contact lens, most particularly a contact lens made from a silicone hydrogel.

[0053] As used herein, the term "ophthalmic device" refers to a device that is in the eye or on the surface of the eye. Such devices can provide optical correction, wound care, tissue repair, drug delivery, diagnostic functionality, or cosmetic enhancement or effect, or a combination of these properties. Useful ophthalmic devices include, but are not limited to, ophthalmic lenses, such as soft contact lenses (e.g., soft contact lenses, hydrogel lenses, soft non-hydrogel lenses, etc.), hard contact lenses (e.g., oxygen permeable hard lens materials, etc.), intraocular lenses, overlay lenses, optical inserts, viscoelastic materials, etc. As those skilled in the art will appreciate, a lens is considered "soft" if it can be folded on itself without breaking.

[0054] The biomedical device to be surface modified according to the present invention can be any material known in the art capable of forming such a biomedical device. In one embodiment, the biomedical device includes a device formed from a material that is not hydrophilic in itself. Such devices are formed from materials known in the art, such as polysilylethanyl, polysiloxane, perfluoropolyether, fluorinated poly(meth)acrylate or equivalent fluorinated polymers derived from, for example, other polymerizable carboxylic acids, polyalkyl(meth)acrylate or equivalent alkyl ester polymers derived from other polymerizable carboxylic acids, or fluorinated polyolefins, such as fluorinated ethylene propylene polymers, or tetrafluoroethylene, preferably in combination with a dioxole (e.g., perfluoro-2,2-dimethyl-1,3-dioxole). Representative examples of suitable bulk materials include, but are not limited to, Samfilcon, Lotrafilcon A, Neofocon, Pasifocon, Telefocon, Silafocon, Fluorsilfocon, Paflufocon, Silafocon, Elastofilcon, Fluorofocon, or Teflon AF (e.g., Teflon AF 1600 or Teflon AF 2400), which are copolymers of about 63 to about 73 mol % perfluoro-2,2-dimethyl-1,3-dioxole and about 37 to about 27 mol % tetrafluoroethylene, or about 80 to about 90 mol % perfluoro-2,2-dimethyl-1,3-dioxole and about 20 to about 10 mol % tetrafluoroethylene.

[0055] In another exemplary embodiment, the biomedical device includes a device formed from a material that is itself hydrophilic because reactive groups (e.g., carboxy, carbamoyl, sulfate, sulfonate, phosphate, amine, ammonium, or hydroxy groups) are inherently present within the material and therefore present on the surface of a biomedical device fabricated therefrom. Such devices are formed from materials known in the art, including, for example, polyhydroxyethyl acrylate, polyhydroxyethyl methacrylate, polyvinylpyrrolidone (PVP), polyacrylic acid, polymethacrylic acid, polyacrylamide, polydimethylacrylamide (DMA), polyvinyl alcohol, and the like, and copolymers thereof (e.g., copolymers derived from two or more monomers selected from hydroxyethyl acrylate, hydroxyethyl methacrylate, N-vinylpyrrolidone, acrylic acid, methacrylic acid, acrylamide, dimethylacrylamide, vinyl alcohol, and the like). Representative examples of suitable bulk materials include, but are not limited to, Polymacon, Tefilcon, Methafilcon, Deltafilcon, Bufilcon, Phemfilcon, Ocufilcon, Focofilcon, Etafilcon, Hefilcon, Vifilcon, Tetrafilcon, Perfilcon, Droxifilcon, Dimefilcon, Isofilcon, Mafilcon, Nelfilcon, Atlafilcon, etc. Other examples of suitable bulk materials include Balafilcon A, Hilafilcon A, Alphafilcon A, Bilafilcon B, Samfilcon, etc.

[0056] In another exemplary embodiment, the biomedical devices surface modified according to the present invention include devices formed from materials that are amphiphilic segmented copolymers comprising at least one hydrophobic segment and at least one hydrophilic segment linked via a bond or bridging member.

[0057] Particularly useful herein is biocompatible material, including both soft and hard materials commonly used in ophthalmic lenses, including contact lenses.Generally, non-hydrogel materials are hydrophobic polymeric materials that do not contain water in their equilibrium state.Typical non-hydrogel materials include silicone acrylics, such as bulky silicone monomers (e.g., tris(trimethylsiloxy)silylpropyl methacrylate, commonly known as "TRIS" monomer), methacrylate end-capped poly(dimethylsiloxane) prepolymers, or silicones with fluoroalkyl side groups (polysiloxanes and polysilylethanes are also commonly known as silicone polymers).

[0058] Hydrogel materials, on the other hand, include hydrated cross-linked polymer systems that contain water in an equilibrium state. Hydrogel materials include about 5 wt.% or more (e.g., up to about 80 wt.%) water. Preferred hydrogel materials include silicone hydrogel materials. In one preferred embodiment, the material includes vinyl-functionalized polydimethylsiloxane copolymerized with hydrophilic monomers, and fluorinated methacrylate and methacrylate-functionalized fluorinated polyethylene oxide copolymerized with hydrophilic monomers. Representative examples of materials suitable for use herein include those disclosed in U.S. Pat. Nos. 5,310,779, 5,387,662, 5,449,729, 5,512,205, 5,610,252, 5,616,757, 5,708,094, 5,710,302, 5,714,557, 5,908,906, 7,915,323, and 8,420,711, the contents of which are incorporated herein by reference.

[0059] In one exemplary embodiment, hydrogel materials for biomedical devices such as contact lenses may include hydrophilic monomers such as one or more unsaturated carboxylic acids, vinyl lactams, amides, polymerizable amines, vinyl carbonates, vinyl carbamates, oxazolone monomers, copolymers thereof, and the like, and mixtures thereof. Useful amides include acrylamides such as N,N-dimethylacrylamide and N,N-dimethylmethacrylamide. Useful vinyl lactams include cyclic lactams such as N-vinyl-2-pyrrolidone. Examples of other hydrophilic monomers include hydrophilic prepolymers such as poly(alkene glycols) functionalized with polymerizable groups. Examples of useful functionalized poly(alkene glycols) include poly(diethylene glycols) of various chain lengths containing monomethacrylate or dimethacrylate end caps. In a preferred embodiment, the poly(alkene glycol) polymer includes at least two alkene glycol monomer units. Still further examples include hydrophilic vinyl carbonate or vinyl carbamate monomers as disclosed in U.S. Patent No. 5,070,215, and hydrophilic oxazolone monomers as disclosed in U.S. Patent No. 4,910,277. Other suitable hydrophilic monomers will be apparent to those skilled in the art. In another embodiment, the hydrogel material may include a siloxane-containing monomer and at least one of the hydrophilic monomers and / or prepolymers described above.

[0060] Non-limiting examples of hydrophobic monomers include C1-C 20 Alkyl and C3-C 20 Cycloalkyl (meth)acrylates, substituted and unsubstituted aryl (meth)acrylates, where the aryl group contains 6 to 36 carbon atoms, (meth)acrylonitrile, styrene, lower alkyl styrenes, lower alkyl vinyl ethers, and C2 to C6 10 Perfluoroalkyl (meth)acrylates and partially fluorinated (meth)acrylates are included.

[0061] A wide variety of materials can be used herein, with silicone hydrogel contact lens materials being particularly preferred. Silicone hydrogels generally have a water content greater than about 5 wt.%, more commonly between about 10 and about 80 wt.%. Such materials are usually prepared by polymerizing a mixture that includes at least one silicone-containing monomer and at least one hydrophilic monomer. Typically, either the silicone-containing monomer or the hydrophilic monomer functions as a crosslinker (a crosslinker is defined as a monomer that has multiple polymerizable functional groups), or separate crosslinkers may be used. Applicable silicone-containing monomers for use in forming silicone hydrogels are well known in the art, with numerous examples shown in U.S. Pat. Nos. 4,136,250, 4,153,641, 4,740,533, 5,034,461, 5,070,215, 5,260,000, 5,310,779, and 5,358,995.

[0062] Representative examples of applicable silicon-containing monomers include bulky polysiloxanylalkyl(meth)acrylic monomers. Examples of bulky polysiloxanylalkyl(meth)acrylic monomers are represented by the structure of Formula I: [ka] [In the formula, X represents -O- or -NR-, R represents hydrogen or C1-C4 alkyl, and each R 1 each independently represents hydrogen or methyl; 2 each independently represents a lower alkyl radical, a phenyl radical, or a group represented by the formula [ka] In the formula, each R 2’ each independently represents a lower alkyl radical or a phenyl radical, and h is 1 to 10.

[0063] Other representative examples of applicable silicon-containing monomers include, but are not limited to, bulky polysiloxanyl alkyl carbamate monomers as generally shown in Formula Ia: [ka] [In the formula, X represents -NR-, R represents hydrogen or C1-C4 alkyl, and R 1 represents hydrogen or methyl, and each R 2 each independently represents a lower alkyl radical, a phenyl radical, or a group represented by the formula [ka] In the formula, each R 2’ each independently represents a lower alkyl radical or a phenyl radical, and h is 1 to 10.

[0064] Examples of bulky monomers are 3-methacryloyloxypropyltris(trimethylsiloxy)silane or tris(trimethylsiloxy)silylpropyl methacrylate (sometimes referred to as TRIS), and tris(trimethylsiloxy)silylpropyl vinylcarbamate (sometimes referred to as TRIS-VC), and the like, and mixtures thereof.

[0065] Such bulky monomers may be copolymerized with silicone macromonomers, which are poly(organosiloxanes) capped with unsaturated groups at two or more ends of the molecule. U.S. Patent No. 4,153,641 discloses various unsaturated groups, such as acryloxy or methacryloxy groups.

[0066] Another class of representative silicone-containing monomers includes, but is not limited to, silicone-containing vinyl carbonate or vinyl carbamate monomers such as 1,3-bis[4-vinyloxycarbonyloxy]but-1-yl]tetramethyl-disiloxane, 3-(trimethylsilyl)propyl vinyl carbonate, 3-(vinyloxycarbonylthio)propyl-[tris(trimethylsiloxy)silane], 3-[tris(trimethylsiloxy)silyl]propyl vinyl carbamate, 3-[tris(trimethylsiloxy)silyl]propyl allyl carbamate, 3-[tris(trimethylsiloxy)silyl]propyl vinyl carbonate, t-butyldimethylsiloxyethyl vinyl carbonate, trimethylsilylethyl vinyl carbonate, trimethylsilylmethyl vinyl carbonate, and the like, and mixtures thereof.

[0067] Another class of silicon-containing monomers includes polyurethane-polysiloxane macromonomers (sometimes referred to as prepolymers), which may have hard-soft-hard blocks like traditional urethane elastomers. They may be end-capped with hydrophilic monomers such as HEMA. Examples of such silicone urethanes are disclosed in various publications, including Lai, Yu-Chin, "The Role of Bulky Polysiloxanylalkyl Methacryates in Polyurethane-Polysiloxane Hydrogels," Journal of Applied Polymer Science, Vol. 60, 1193-1199 (1996). PCT Published Application No. WO 96 / 31792 discloses examples of such monomers, the disclosure of which is incorporated herein by reference in its entirety. Further examples of silicone urethane monomers are represented by formulas II and III: E(*D*A*D*G) a *D*A*D*E'; or (II) E(*D*G*D*A) a *D*A*D*E'; or (III) [In the formula, D independently represents an alkyl diradical, an alkylcycloalkyl diradical, a cycloalkyl diradical, an aryl diradical, or an alkylaryl diradical having from 6 to about 30 carbon atoms; G independently represents an alkyl diradical, a cycloalkyl diradical, an alkylcycloalkyl diradical, an aryl diradical, or an alkylaryl diradical having from 1 to about 40 carbon atoms, which may contain an ether linkage, a thio linkage, or an amine linkage in the backbone; * indicates a urethane bond or a ureido bond. a is at least 1, A independently represents a divalent polymer radical of formula IV, [ka] (In the formula, each R s independently represent an alkyl group or a fluoro-substituted alkyl group having 1 to about 10 carbon atoms which may contain an ether bond between the carbon atoms, m' is at least 1, and p is a number representing a moiety weight of about 400 to about 10,000. each of E and E′ independently represents a polymerizable unsaturated organic radical represented by formula V, [ka] (In the formula, R 3 is hydrogen or methyl, R 4 is hydrogen, an alkyl radical having 1 to 6 carbon atoms, or -CO-YR 6 a radical, wherein Y is -O-, -S-, or -NH-; R 5 is a divalent alkylene radical having 1 to about 10 carbon atoms, R 6 is an alkyl group having 1 to about 12 carbon atoms; X represents -CO- or -OCO-; Z represents -O- or -NH-; Ar represents an aromatic radical having from about 6 to about 30 carbon atoms; w is 0 to 6, x is 0 or 1, y is 0 or 1, and z is 0 or 1).

[0068] A preferred silicone-containing urethane monomer is represented by Formula VI: [ka] wherein m is at least 1, preferably 3 or 4; a is at least 1, preferably 1; p is a number representing a moiety weight of from about 400 to about 10,000, preferably at least about 30; R 7 is the diradical of a diisocyanate after removal of the isocyanate group (e.g., the diradical of isophorone diisocyanate), and each E″ is a group represented by [ka]

[0069] In another exemplary embodiment, the silicone hydrogel material comprises (in bulk, i.e., in the copolymerized monomer mixture) about 5 to about 50 weight percent, preferably about 10 to about 25 weight percent, of one or more silicone macromonomers, about 5 to about 75 weight percent, preferably about 30 to about 60 weight percent, of one or more polysiloxanylalkyl(meth)acrylic monomers, and about 10 to about 50 weight percent, preferably about 20 to about 40 weight percent, of a hydrophilic monomer. Generally, silicone macromonomers are poly(organosiloxanes) in which two or more ends of the molecule are capped with unsaturated groups. In addition to the end groups in the above structural formula, U.S. Pat. No. 4,153,641 discloses additional unsaturated groups, including acryloxy or methacryloxy. Fumarate-containing materials (e.g., those disclosed in U.S. Pat. Nos. 5,310,779, 5,449,729, and 5,512,205) are also useful substrates according to the present invention. The silane macromonomer can be a silicone-containing vinyl carbonate or vinyl carbamate or polyurethane-polysiloxane having one or more hard-soft-hard blocks endcapped with a hydrophilic monomer.

[0070] Another representative class of silicone-containing monomers includes fluorinated monomers.Such monomers are used in the formation of fluorosilicone hydrogels to reduce the accumulation of deposits on contact lenses made from fluorosilicone hydrogels, as disclosed in, for example, U.S. Patent Nos. 4,954,587, 5,010,141, 5,079,319 and 7,994,356.In addition, the use of silicone-containing monomers with certain fluorinated side groups, i.e., -(CF2)-H, has been found to improve the compatibility between hydrophilic monomer units and silicone-containing monomer units.See, for example, U.S. Patent Nos. 5,321,108 and 5,387,662.

[0071] The above silicone materials are merely exemplary, and other materials that can benefit from coating with the hydrophilic coating composition of the present invention, which are disclosed in various publications and are continually being developed for use in contact lenses and other medical devices, can also be used as substrates.For example, the biomedical device can be formed from at least one cationic monomer, such as a cationic silicone-containing monomer or a cationic fluorinated silicone-containing monomer.

[0072] Contact lenses for application of the present invention can be manufactured using various conventional techniques to obtain molded articles with desired posterior and anterior lens surfaces. Spin casting methods are disclosed in U.S. Pat. Nos. 3,408,429 and 3,660,545, and static casting methods are disclosed in U.S. Pat. Nos. 4,113,224, 4,197,266, and 5,271,876. After curing of the monomer mixture, machining operations can be performed to obtain contact lenses with the desired final configuration. As an example, U.S. Pat. No. 4,555,732 discloses a method in which an excess of a monomer mixture is cured by spin casting in a mold to form a relatively thick molded article with anterior lens surface. The posterior surface of the cured spin cast article is then lathe cut to obtain contact lenses with the desired thickness and posterior lens surface. Further machining operations may be performed after lathe cutting of the lens surface (e.g., edge finishing operations).

[0073] Typically, the initial monomer mixture contains an organic diluent to minimize phase separation of the polymerization product produced by polymerization of the monomer mixture and to reduce the glass transition temperature of the reacting polymer mixture. This makes the curing process more efficient and ultimately results in a more uniformly polymerized product. It is particularly important for silicone hydrogels that the initial monomer mixture and polymerization product are sufficiently uniform. The main reason for this is the inclusion of silicone-containing monomers that may tend to separate from hydrophilic comonomers.

[0074] Suitable organic diluents include, for example, C6-C 10 Examples of suitable diluents include monohydric alcohols such as linear aliphatic monohydric alcohols (e.g., n-hexanol and n-nonanol), diols such as ethylene glycol, polyols such as glycerin, ethers such as diethylene glycol monoethyl ether, ketones such as methyl ethyl ketone, esters such as methyl enanthate, and hydrocarbons such as toluene. The organic diluent is preferably sufficiently volatile to facilitate removal from the cured article by evaporation at or near atmospheric pressure.

[0075] Generally, the diluent can comprise from about 5 to about 60 weight percent of the monomer mixture, with from about 10 to about 50 weight percent being particularly preferred. If necessary, the cured lens can be subjected to solvent removal. Solvent removal can be accomplished by evaporation at or near atmospheric pressure or under vacuum. Elevated temperatures can be used to reduce the time required to evaporate the diluent.

[0076] After the organic diluent is removed, the lens can be subjected to demolding and optional machining operations. Machining steps include, for example, buffing or polishing the edges and / or surfaces of the lens. Generally, such machining processes can be performed before or after the article is released from the mold part. As an example, the lens can be dry released from the mold by lifting the lens from the mold with vacuum tweezers.

[0077] As those skilled in the art will readily understand, the biomedical device surface functional groups of the biomedical device according to the present invention may be inherently present on the surface of the device. However, if the biomedical device contains too few or no functional groups, the surface of the device can be modified by known techniques, such as plasma chemistry (see, for example, WO94 / 06485), or traditional functionalization with groups such as -OH or -CO2H. Suitable biomedical device surface functional groups in biomedical devices include a wide variety of groups well known to those skilled in the art. Representative examples of such functional groups include, but are not limited to, hydroxy groups, cis 1,2-diols, cis 1,3-diols, alpha hydroxy acid groups (e.g., sialic acid, salicylic acid), carboxylic acids, dicarboxylic acids, catechols, silanols, silicates, and the like.

[0078] In one exemplary embodiment, the biomedical device is subjected to an oxidative surface treatment, such as corona discharge or plasma oxidation, and then treated with the glycophospholipid polymer and / or crosslinked glycophospholipid polymer network of the present invention.For example, the biomedical device, such as a silicone hydrogel formulation containing a hydrophilic polymer (e.g., poly(N,N-dimethylacrylamide) or poly(N-vinylpyrrolidinone)), is subjected to an oxidative surface treatment to form at least silicates on the surface of the lens, and then the lens is treated with an aqueous solution containing the glycophospholipid polymer and / or crosslinked glycophospholipid polymer network of the present invention to provide a lubricating, stable and highly wettable surface coating.The complex formation treatment is advantageously carried out under autoclave conditions (sterile conditions).

[0079] Standard processes such as plasma processes (also referred to as "electrical glow discharge processes") provide a thin and durable surface to the biomedical device prior to bonding of the glycophospholipid polymer and / or cross-linked glycophospholipid polymer network to at least a portion of the surface of the biomedical device. Examples of such plasma processes are shown in U.S. Patent Nos. 4,143,949, 4,312,575, and 5,464,667.

[0080] Plasma processes are widely known in the art, but a brief overview is given below. Plasma surface treatment involves passing an electric discharge through a gas at low pressure. The discharge can be radio frequency (typically 13.56 MHz), but microwave and other frequencies may also be used. The discharge produces ultraviolet (UV) radiation that, in addition to being absorbed by the gaseous atoms and molecules, results in the production of highly energetic electrons and ions, atoms (ground and excited states), molecules, and radicals. Thus, the plasma is a complex mixture of atoms and molecules in both ground and excited states, which reaches a steady state after the discharge is initiated. A circulating electric field causes these excited atoms and molecules to collide with each other, the walls of the chamber, and the surface of the material being treated.

[0081] Coating deposition of materials onto surfaces from plasma has been shown to be possible from high energy plasma without the assistance of sputtering (sputter assisted deposition). Monomers can be deposited from the gas phase and polymerized on the substrate using a suitably high continuous or pulsed plasma of about 1000 watts in a low pressure atmosphere (e.g., about 0.005 to about 5 Torr, or about 0.001 to about 1 Torr). Modulated plasma can be applied, for example, on and off for about 100 milliseconds. In addition, liquid nitrogen cooling has been used to condense vapors from the gas phase onto the substrate, and plasma is then used to chemically react these materials with the substrate. However, plasma does not require the use of external cooling or heating to deposit. At low or high wattage (e.g., about 5 to about 1000, or about 20 to about 500 watts), plasma can coat even the most chemically resistant substrates, including silicone.

[0082] After initiation by a low-energy discharge, collisions between high-energy free electrons present in the plasma lead to the formation of ions, excited molecules, and free radicals. Once formed, such species not only react with themselves in the gas phase, but also with ground-state molecules. Plasma processing can be understood as an energy-dependent process involving high-energy gas molecules. In order to cause a chemical reaction at the surface of the lens, species (elements or molecules) are required in terms of charge state and particle energy. Radio frequency plasmas generally generate a distribution of high-energy species. Typically, "particle energy" refers to the average of the so-called Boltzmann-type distribution of energy for the high-energy species. In low-density plasmas, the electron energy distribution can be related by the ratio of the electric field strength that sustains the plasma to the discharge voltage (E / p). As will be appreciated by those skilled in the art, the plasma power density P is a function of wattage, pressure, gas flow rate, etc.Background information on plasma technology, which is incorporated herein by reference, includes the following: A.T. Bell, Proc. Intl. Conf. Phenom. Ioniz. Gases, "Chemical Reaction in Nonequilibrium Plasmas", 19-33 (1977); J.M. Tibbett, R. Jensen, A.T. Bell, M. Shen, Macromolecules, "A Model for the Kinetics of Plasma Polymerization", 3, 648-653 (1977); J.M. Tibbett, M. Shen, A.T. Bell, J. Macromol. Sci.-Chem., "Structural Characterization of Plasma-Polymerized Hydrocarbons", A10, 1623-1648 (1976); C.P. Ho, H. Yasuda, J. Biomed. Mater. Res., "Ultrathin coating of plasma polymer of methane applied on the surface of silicone contact lenses”,22,919-937(1988);H.Kobayashi,ATBell,M.Shen,Macromolecules,“Plasma Polymerization of Saturated and Unsaturated Hydrocarbons”,3,277-283(1974);RYChen,USPat.No.,4,143,949,Mar.13,1979,“Process for Putting a Hydrophilic Coating on a Hydrophobic Contact lens”;and H.Yasuda,HCMarsh,MOBumgarner,N.Morosoff,J.of Appl.Poly.Sci., “Polymerization of Organic Compounds in an Electroless Glow Discharge.VI.Acetylene with Unusual Co-monomers”, 19, 2845-2858 (1975).

[0083] Based on previous research in the field of plasma technology, it is possible to understand the effect of pressure and discharge power changes on the plasma modification rate. This rate generally decreases as the pressure increases. Thus, as the pressure increases the value of E / p, the ratio of the electric field strength sustaining the plasma to the gas pressure decreases, causing a decrease in the average electron energy. The decrease in electron energy in turn decreases the rate coefficients of all electron-molecule collision processes. A further consequence of increasing pressure is a decrease in electron density. If the pressure is kept constant, there should be a linear relationship between electron density and power.

[0084] In practice, contact lenses are surface treated by placing them in an electric glow discharge reaction vessel (e.g., a vacuum chamber) in a non-hydrated state. Such reaction vessels are commercially available. The lens may be supported in the vessel on an aluminum tray (which acts as an electrode) or on other support devices designed to adjust the position of the lens. The use of specialized support devices that allow for surface treatment of both sides of the lens is known in the art and can be used herein.

[0085] As mentioned above, the surface of a lens (e.g., a silicone hydrogel continuous wear lens) is first treated (e.g., oxidized) by the use of plasma to allow subsequent surface attachment of glycophospholipid polymer and / or cross-linked glycophospholipid polymer network to be more adhesive to the lens. Such plasma treatment of the lens can be accomplished in an atmosphere composed of a suitable medium, e.g., an oxidizing medium such as oxygen, air, water, peroxide, O2 (oxygen gas), or a suitable combination thereof, typically at a discharge frequency of about 13.56 MHz, preferably between about 20 and about 500 watts, at a pressure of about 0.1 to about 1.0 Torr, for a period of time preferably from about 10 seconds to about 10 minutes or more, more preferably from about 1 to about 10 minutes. It is preferred that this step utilizes a relatively "intense" plasma, e.g., ambient air drawn through a five percent (5%) hydrogen peroxide solution. Those skilled in the art will be aware of other methods to improve or promote adhesion for subsequent attachment of the glycophospholipid polymer and / or cross-linked glycophospholipid polymer network layer.

[0086] The biomedical device is then subjected to a surface treatment according to the present invention. In general, a biomedical device, such as a wettable silicone-based hydrogel lens, is contacted with a solution containing at least one of the glycophospholipid polymers and / or cross-linked glycophospholipid polymer networks of the present invention, whereby the glycophospholipid polymers and / or cross-linked glycophospholipid polymer networks form complexes with a plurality of biomedical device surface functional groups on the surface of the biomedical device. The biomedical device may be directly contacted with the solution containing at least the glycophospholipid polymers and / or cross-linked glycophospholipid polymer networks in the mold assembly, or the biomedical device may be removed from the mold assembly and then contacted with the solution. The solution is a water-based solution containing the glycophospholipid polymers and / or cross-linked glycophospholipid polymer networks, which may result in a lubricious, stable and highly wettable surface. The complex formation treatment is advantageously carried out under autoclave conditions.

[0087] Generally, these solutions include compositions for direct instillation into the eye, including eye drop solutions, contact lens treatment solutions that are dropped directly into the eye, for example, to rewet the contact lens while it is being worn, and those that qualify as multi-purpose solutions. Ophthalmic compositions also include compositions that are indirectly injected into the eye, such as contact lens treatment solutions for treating contact lenses prior to their insertion into the eye or packaging solutions for storing lenses.

[0088] The ophthalmically acceptable solution according to the present invention is physiologically compatible. Specifically, the composition must be "ophthalmically safe" for use with contact lenses. This means that contact lenses treated with the solution are generally suitable and safe for direct placement on the eye without rinsing, i.e., the solution is safe and comfortable for daily contact with the eye through a contact lens moistened with the solution. An ophthalmically safe composition has a tonicity and pH that is compatible with the eye, and contains materials and amounts of materials that are non-cytotoxic according to ISO (International Standards Organization) standards and US FDA regulations. The composition should also be sterile, in that the absence of microbial contaminants in the product prior to shipping must be statistically demonstrated to the extent necessary for such products.

[0089] Generally, one or more of the glycophospholipid polymers and / or cross-linked glycophospholipid polymer networks of the present invention may be present in an ophthalmic solution in an amount ranging from about 0.001 to about 10% w / w. In one exemplary embodiment, one or more of the glycophospholipid polymers and / or cross-linked glycophospholipid polymer networks of the present invention may be present in an ophthalmic solution in an amount ranging from about 0.1 to about 2% w / w.

[0090] Ophthalmic solutions can be in the form of drops and are useful as components of contact lens cleaning, disinfecting, or conditioning compositions that include such materials. In one embodiment, the compositions and / or solutions of the present invention can be formulated as "multi-purpose solutions". Multi-purpose solutions are useful for cleaning, disinfecting, storing, and rinsing lenses, especially soft contact lenses. Multi-purpose solutions do not exclude the possibility that some wearers (e.g., wearers who are particularly sensitive to chemical disinfectants or other chemical agents) may prefer to rinse or wet their contact lenses with a separate solution (e.g., sterile saline) before inserting them. The term "multi-purpose solution" also does not exclude the possibility of periodic cleaning agents that are not used on a daily basis, or supplemental cleaning agents for further protein removal, such as enzymatic cleaners that are typically used on a weekly basis. The term "cleaning" means that the solution contains one or more agents in a concentration sufficient to loosen and remove lens deposits and other contaminants loosely held on the surface of the contact lens, which may be used in combination with manual action (e.g., manually scrubbing the lens with the solution) or with an auxiliary device that agitates the solution in contact with the lens, e.g., a mechanical cleaning aid.

[0091] Traditionally, commercially available multi-purpose solutions require a regimen involving mechanical scrubbing of lenses with the multi-purpose solution to provide the necessary disinfection and cleaning. Such a regimen is required for chemical disinfection systems that do not qualify as chemical disinfection solutions under government regulatory agencies (e.g., FDA or the US Food and Drug Administration (FDA)). In one embodiment of the present invention, it is possible to formulate a cleaning and disinfection product that, on the one hand, can provide improved cleaning and disinfection in the absence of a scrubbing regimen, and, on the other hand, is gentle enough to be used as a wetting agent, e.g., as an eye drop. For example, a product that qualifies as a chemical disinfection solution must meet the biocidal performance standards established by the US FDA for contact lens care products (May 1, 1997), which do not involve scrubbing of lenses. In one embodiment of the present invention, the composition is formulated to meet the requirements of the FDA or ISO stand-alone procedures for contact lens disinfection products. Similarly, the compositions of the present invention can be formulated to provide enhanced cleaning without the use of a scrubbing regimen. Such a formulation can ensure higher patient compliance and greater universal appeal than conventional multi-purpose disinfection and cleaning products. The viscosity of the general-purpose solution may be less than about 75 cps, or from about 1 to about 50 cps, or from about 1 to about 25 cps, or at least about 95 weight percent water by volume in the total composition.

[0092] The aqueous ophthalmic solution may contain one or more antimicrobial agents, preservatives, etc., in addition to one or more of the glycophospholipid polymers and / or crosslinked glycophospholipid polymer networks of the present invention. The composition generally includes a primary antimicrobial agent. Antimicrobial agents suitable for use in the present invention include chemicals that induce antimicrobial activity through chemical or physicochemical interactions with microorganisms. Such agents may be used alone or in combination.

[0093] Suitable known ophthalmically acceptable antimicrobial agents include, but are not limited to, biguanides or salts or free bases thereof, quaternary ammonium compounds or salts or free bases thereof, terpenes or derivatives thereof, branched glycerol monoalkyl ethers, branched glycerol monoalkyl amines, branched glycerol monoalkyl sulfides, fatty acid monoesters (wherein the fatty acid monoesters include an aliphatic fatty acid moiety having 6 to 14 carbon atoms and an aliphatic hydroxyl moiety), amidoamine compounds, and the like, and combinations thereof.

[0094] The biguanide antimicrobial agent suitable for use in the ophthalmic composition can be any biguanide or salt thereof known in the art. Representative biguanides include non-polymeric biguanides, polymeric biguanides, their salts, their free bases, etc., and mixtures thereof. Representative non-polymeric biguanides include bis(biguanides), such as alexidine, chlorhexidine, salts of alexidine (e.g., alexidine HCl), salts of chlorhexidine, alexidine free base, etc., and mixtures thereof. The alexidine and chlorhexidine salts can be either organic or inorganic, and are typically disinfectant nitrates, acetates, phosphates, sulfates, halides, etc.

[0095] Representative polymeric biguanides include polymeric hexamethylene biguanide (PHMB) (commercially available from Zeneca, Wilmington, Del.), polymers and water-soluble salts thereof. In one embodiment, the water-soluble polymeric biguanides used herein can have a number average molecular weight of at least about 1,000, or from about 1,000 to about 50,000. Suitable water-soluble salts of the free base include, but are not limited to, hydrochloride, borate, acetate, gluconate, sulfonate, tartrate, and citrate salts. Generally, hexamethylene biguanide polymers (also referred to as polyaminopropyl biguanide (PAPB)) have a number average molecular weight of up to about 100,000. Such compounds are known and are disclosed in U.S. Pat. No. 4,758,595, incorporated herein by reference.

[0096] PHMB is best described as a polymeric biguanide composition comprising at least three, and preferably at least six, biguanide polymers, referred to herein as PHMB-A, PHMB-CG, and PHMB-CGA, whose general chemical structures are shown below. [ka]

[0097] For each of these polymers, "n" represents the average number of repeating groups. In reality, there is a distribution of polymer lengths for each of the polymers shown. The traditional synthetic route to PHMB resulted in a polymeric biguanide composition with about 50% by weight of the polymer composition as PHMB-CGA, i.e., with a cyanoguanidino end cap at one end and an amine at the other, with about 25% by weight PHMB-A and about 25% by weight PHMB-CG. Assuming the approximate weight ratios for the three major PHMB polymers above, the percentage of cyanoguanidino end caps is also about 50% of the total number of end groups. In this application, this traditional polymeric biguanide composition is referred to as poly(hexamethylene biguanide) or PHMB.

[0098] Also, 13 Polymeric biguanide compositions containing less than 18 mole percent terminal amine groups as measured by C-NMR may also be used. The polymeric biguanide compositions may also be characterized by a relative increase in the molar concentration of terminal guanidine groups or terminal cyanoguanidino groups. For example, in one embodiment, the biguanide composition contains less than about 18 mole percent terminal amine groups and greater than or equal to about 40 mole percent terminal guanidine groups. In another embodiment, the biguanide composition contains less than about 18 mole percent terminal amine groups and greater than or equal to about 55 mole percent terminal guanidine groups.

[0099] In this application, this biguanide composition is referred to as PHMB-CG*. The polymeric biguanide composition is also referred to generically as "hexamethylene biguanide," which one of skill in the art will recognize as including both PHMB and PHMB-CG*.

[0100] Representative examples of quaternary ammonium compounds suitable for use in the ophthalmic compositions of the present invention include, but are not limited to, poly[(dimethyliminio)-2-butene-1,4-diyl chloride] and [4-tris(2-hydroxyethyl)ammonio]-2-butenyl-w-[tris(2-hydroxyethyl)ammonio]-dichloride (Chemical Registry Number 75345-27-6) (commonly available as Polyquaternium 1 under the trade name ONAMER® M (Stepan Company, Northfield, Ill.)) and mixtures thereof.

[0101] Terpene antimicrobial agents suitable for use in the ophthalmic compositions of the present invention include any monoterpene, sesquiterpene, and / or diterpene, or derivatives thereof. Acyclic, monocyclic, and / or bicyclic mono-, sesqui-, and / or diterpenes, as well as those with a higher number of rings, can be used. As used herein, a "derivative" of a terpene is understood to mean a terpene hydrocarbon having one or more functional groups (e.g., terpene alcohols, terpene ethers, terpene esters, terpene aldehydes, terpene ketones, etc., and combinations thereof). Both trans and cis isomers are suitable herein. The terpene moiety in the terpenes and derivatives can contain from 6 to about 100 carbon atoms, preferably from about 10 to about 25 carbon atoms.

[0102] Representative examples of suitable terpene alcohol antimicrobial agents include verbenol, trans pinocarveol, cis-2-pinanol, nopol, isoborneol, carveol, piperitol, thymol, α-terpineol, terpinen-4-ol, menthol, 1,8-terpine, dihydro-terpineol, nerol, geraniol, linalool, citronellol, hydroxycitronellol, 3,7-dimethyloctanol, dihydro-myrcenol, tetrahydro-allo-ocimenol, perillic alcohol, falcarindiol, and the like, and mixtures thereof.

[0103] Representative examples of suitable terpene ether and terpene ester antimicrobial agents include 1,8-cineole, 1,4-cineole, isobornyl methyl ether, rosopyran, alpha-terpinyl methyl ether, menthofuran, trans-anethole, methyl chavicol, alloocimene diepoxide, limonene mono-epoxide, isobornyl acetate, nonyl acetate, alpha-terpinyl acetate, linalyl acetate, geranyl acetate, citronellyl acetate, citronellyl acetate, dihydro-terpinyl acetate, meryl acetate, and the like, and mixtures thereof.

[0104] Representative examples of terpene aldehydes and terpene ketone antimicrobial agents include myrtenal, campholenic aldehyde, perillaldehyde, citronellal, citral, hydroxycitronellal, camphor, verbenone, carbenone, dihydro-carvone, carvone, piperitone, menthone, geranylacetone, pseudo-ionone, α-ionine, iso-pseudo-methylionone, n-pseudo-methylionone, iso-methylionone, n-methylionone, and the like, and mixtures thereof. Any other terpene hydrocarbon having a functional group known in the art may be used in the compositions of the present invention.

[0105] In one exemplary embodiment, terpenes or derivatives thereof suitable as antimicrobial agents include, but are not limited to, tricyclene, α-pinene, terpinolene, carveol, amyl alcohol, nerol, β-santalol, citral, pinene, nerol, b-ionone, caryophyllene (from clove), guaiol, anisaldehyde, cedrol, linalool, d-limonene (orange oil, lemon oil), longifolene, anisyl alcohol, patchouli alcohol, α-cadinene, 1,8-cineole, ρ-cymene, 3-carene, ρ-8-menthane, trans-menthone, borneol, α-fenchol, isoaza, α-sulfuric acid ... Myracetate, terpines, cinnamaldehyde, ionones, geraniol (from roses and other flowers), myrcene (from bayberry wax, bay oil and verbena oil), nerol, citronellol, carvacrol, eugenol, carvone, alpha-terpineol, anethole, camphor, menthol, limonene, nerolidol, farnesol, phytol, carotene (vitamin A1), squalene, thymol, tocotrienols, perillyl alcohol, borneol, simene, carene, terpenes, linalool, 1-terpene-4-ol, zingiberene (from ginger), and the like, and mixtures thereof.

[0106] In one exemplary embodiment, the compound of component (ii) of the ophthalmic composition comprises a branched glycerol monoalkyl ether. In another embodiment, the compound of component (ii) of the ophthalmic composition comprises a branched glycerol monoalkyl amine. In another embodiment, the compound of component (ii) of the ophthalmic composition comprises a branched glycerol monoalkyl sulfide. In yet another embodiment, the compound of component (ii) of the ophthalmic composition comprises a mixture of any one of a branched glycerol monoalkyl ether, a branched glycerol monoalkyl amine, or a branched glycerol monoalkyl sulfide.

[0107] In one exemplary embodiment, the branched glycerol monoalkyl ether for use in the ophthalmic composition of the present invention is 3-[(2-ethylhexyl)oxy]-1,2-propanediol (EHOPD). In another embodiment, the branched glycerol monoalkylamine is 3-[(2-ethylhexyl)amino]-1,2-propanediol (EHAPD). In another embodiment, the branched glycerol monoalkylsulfide is 3-[(2-ethylhexyl)thio]-1,2-propanediol (EHSPD). In yet another embodiment, the ophthalmic composition comprises a mixture of any one of EHOPD, EHAPD, and EHSPD. The chemical structures of EHOPD, EHAPD, and EHSPD are shown below. [ka]

[0108] EHOPD is also called octoxyglycerin and is sold under the trade name Sensiva® SC50 (Schulke & Mayr). EHOPD is a branched glycerol monoalkyl ether that is gentle on the skin and exhibits antimicrobial activity against gram-positive bacteria (e.g., Micrococcus luteus, Corynebacterium aquaticum, Corynebacterium flavescens, Corynebacterium callunae, Corynebacterium nephredi). Thus, EHOPD is used in various skin deodorant preparations at concentrations between about 0.2 and 3 percent by weight. EHAPD can be prepared from 2-ethylhexylamine and 2,3-epoxy-1-propanediol using chemistry well known to those skilled in the art. EHSPD can be prepared from 2-ethylhexylthiol and 2,3-epoxy-1-propanediol using chemistry well known to those skilled in the art.

[0109] Fatty acid monoesters suitable for use in the ophthalmic compositions of the present invention include those containing an aliphatic fatty acid moiety having 6 to 14 carbon atoms and an aliphatic hydroxyl moiety.

[0110] The term "aliphatic" refers to straight or branched chain, saturated or unsaturated hydrocarbons having 6-14 carbon atoms. In one embodiment, the aliphatic fatty acid moiety is a straight chain, saturated or unsaturated hydrocarbon having 8-10 carbons. In another embodiment, the aliphatic fatty acid moiety is a branched chain, saturated or unsaturated hydrocarbon having 8-10 carbons.

[0111] The aliphatic hydroxyl moiety of the fatty acid monoester can be any aliphatic compound having at least one hydroxyl group. In many embodiments, the aliphatic hydroxyl moiety has 3-9 carbons. The aliphatic hydroxyl moiety can include, but is not limited to, propylene glycol, glycerol, polyalkylene glycols (e.g., polyethylene glycol or polypropylene glycol), cyclic polyols (e.g., sorbitan, glucose, mannose, sucrose, fructose, fucose, and inisitol, and derivatives thereof), and linear polyols (e.g., mannitol and sorbitol, and derivatives thereof), and the like, and mixtures thereof.

[0112] Representative examples of amidoamines suitable for use in the ophthalmic compositions of the present invention include those having the general formula: 15 -(OCH2CH2) m -X-(CH2) n -Y amidoamine, where R 15 is C6~C 30 is a saturated or unsaturated hydrocarbon (including, by way of example, linear or branched, substituted or unsubstituted alkyl, alkylaryl, or alkoxyaryl groups), m is zero to 16, n is 2 to 16, and X is -C(O)-NR 16 -or-R 16 NC(O)- and Y is -N(R 17 )2(wherein, R 16 and R 17 each independently is hydrogen, C1-C8 saturated or unsaturated alkyl, or hydroxyalkyl), or a pharma- ceutically acceptable salt thereof.

[0113] Some of the amidoamines utilized in the present invention are available from commercial sources. For example, myristamidopropyl dimethylamine is available from Alcon Inc. (Fort Worth, Tx.) under the trade name Aldox®, lauramidopropyl dimethylamine is available from Inolex Chemical Company (Philadelphia, Pa.) under the trade name LEXAMINE® L-13, and stearamidopropyl dimethylamine is also available from Inolex Chemical Company as LEXAMINE® S-13. The above amidoamines can be synthesized according to known techniques, including those described in U.S. Pat. No. 5,573,726.

[0114] The amount of the primary antimicrobial agent may vary depending on the particular agent used. In the case of the aforementioned organic nitrogen-containing agents, typically such agents are present in concentrations ranging from about 0.00001 to about 0.5 wt.% or about 0.00003 to about 0.05 wt.%. Higher amounts may be required in the case of sorbic acid, typically about 0.01 to about 1 wt.%, or about 0.1 to about 0.5 wt.%. The antimicrobial agent is preferably used in an amount that at least partially reduces the microbial population in the formulation used. If desired, the antimicrobial agent may be used in a disinfecting amount that reduces the microbial bioburden by at least the order of 2 logs in 4 hours, more preferably by the order of 1 log in 1 hour. The disinfecting amount is most preferably an amount that removes the microbial load on contact lenses when used in the recommended soaking time regimen (FDA Chemical Disinfectant Effectiveness Testing - July 1985 Contact Lens Solution Draft Guideline).

[0115] The aqueous solution may further include one or more other components commonly present in ophthalmic solutions, such as, for example, surfactants, tonicity adjusting agents, buffering agents, chelating agents, pH adjusting agents, viscosity modifiers, and demulcents, as discussed above, which are useful in making the ophthalmic compositions more comfortable for the user and / or more effective in their intended use.

[0116] The pH of the solutions and / or compositions according to the invention can be maintained within a pH range of about 4.0 to about 9.0, or about 5.0 to about 8.0, or about 6.0 to about 8.0, or about 6.5 to about 7.8. In one embodiment, the pH value is up to about 7 or higher.

[0117] In one exemplary embodiment, the biomedical device is transferred to an individual lens package containing a buffered saline solution containing at least one of the glycophospholipid polymers and / or cross-linked glycophospholipid polymer networks of the present invention. In general, a packaging system for storing an ophthalmic device according to the present invention includes at least one sealed container that contains one or more unused ophthalmic devices immersed in an aqueous packaging solution. In one embodiment, the sealed container is a hermetically sealed blister pack in which a concave well that contains an ophthalmic device such as a contact lens is covered with a metal or plastic sheet that is adapted to be peeled to open the blister pack. The sealed container can be any suitable generally inert packaging material that provides a reasonable degree of protection for the lens, preferably a plastic material such as polyalkylene, PVC, polyamide, etc.

[0118] The amount of one or more glycophospholipid polymers and / or cross-linked glycophospholipid polymer networks used in the packaging solution for storing an ophthalmic device in the packaging system of the present invention is an amount effective to improve the surface properties of the ophthalmic device. The glycophospholipid polymers and / or cross-linked glycophospholipid polymer networks are believed to enhance initial and long-term comfort when a contact lens packaged in the solution and then removed from the packaging system is placed on an eye for wear. In one exemplary embodiment, the concentration of the one or more glycophospholipid polymers and / or cross-linked glycophospholipid polymer networks in the packaging solution ranges from about 0.01 to about 20% w / w. In one exemplary embodiment, the concentration of the one or more glycophospholipid polymers and / or cross-linked glycophospholipid polymer networks present in the packaging solution ranges from about 0.02 to about 0.1% w / w.

[0119] The packaging solution according to the present invention is physiologically compatible. Specifically, the solution must be "ophthalmically safe" for use with lenses, such as contact lenses. This means that contact lenses treated with the solution are generally suitable and safe for direct placement on the eye without rinsing, i.e., the solution is safe and comfortable for daily contact with the eye through a contact lens moistened with the solution. An ophthalmically safe solution has a tonicity and pH that is compatible with the eye, and contains materials and amounts of materials that are non-cytotoxic according to ISO standards and U.S. Food and Drug Administration (FDA) regulations.

[0120] The packaging solution should also be sterile in the sense that the absence of microbial contaminants in the product prior to shipping must be statistically proven to the extent necessary for such products. The liquid medium useful in the present invention is selected so as not to have a substantial detrimental effect on the lens being treated or cared for, and is selected so as to enable or even facilitate the lens treatment(s) of the present invention. In one embodiment, the liquid medium is aqueous-based. Particularly useful aqueous liquid media are those derived from saline, such as conventional saline or conventional buffered saline.

[0121] The pH of the packaging solution should be maintained within the range of about 6 to about 9 or about 6.5 to about 7.8. Suitable buffers may be added, such as boric acid, sodium borate, potassium citrate, citric acid, sodium bicarbonate, TRIS, and various mixed phosphate buffers (including combinations of Na2HPO4, NaH2PO4, and KH2PO4), and mixtures thereof. Generally, the buffer is used in an amount ranging from about 0.05 to about 2.5 percent by weight of the solution. In one embodiment, the buffer is used in an amount ranging from about 0.1 to about 1.5 percent by weight of the solution. In one embodiment, the packaging solution of the present invention comprises a borate buffer, such as a borate buffer comprising one or more of boric acid, sodium borate, potassium tetraborate, potassium metaborate, or mixtures thereof. In another embodiment, the packaging solution of the present invention comprises a phosphate buffer.

[0122] Typically, the packaging solution is also adjusted with a tonicity agent to approximate the osmolality of normal tears, equivalent to a 0.9 percent sodium chloride solution or a 2.5 percent glycerol solution. The packaging solution is made substantially isotonic with saline, used alone or in combination. If it is not, and is instead simply mixed with sterile water to make it hypotonic or hypertonic, the lens will lose its desirable optical parameters. Similarly, excess saline can form a hypertonic solution, causing stinging and eye irritation.

[0123] Suitable tonicity adjusting agents include, for example, sodium and potassium chloride, dextrose, glycerin, calcium and magnesium chloride, and the like, and mixtures thereof. These tonicity adjusting agents are typically used individually in an amount ranging from about 0.01 to about 2.5% w / v. In one exemplary embodiment, the tonicity adjusting agent is used in an amount ranging from about 0.2 to about 1.5% w / v. The tonicity adjusting agent is used in an amount that results in a final osmolality value of at least about 200 mOsm / kg. In one exemplary embodiment, the tonicity adjusting agent is used in an amount that results in a final osmolality value of about 200 to about 400 mOsm / kg. In one exemplary embodiment, the tonicity adjusting agent is used in an amount that results in a final osmolality value of about 250 to about 350 mOsm / kg. In one exemplary embodiment, the tonicity adjusting agent is used in an amount that results in a final osmolality value of about 280 to about 320 mOsm / kg.

[0124] If desired, one or more additional components can be included in the packaging solution. Such additional component(s) are selected to impart or provide at least one beneficial or desired property to the packaging solution. Generally, the additional components can be selected from ingredients that are conventionally used in one or more ophthalmic device care compositions. Suitable additional components include, for example, cleaning agents, wetting agents, nutrients, sequestering agents, viscosity imparting agents, contact lens conditioning agents, antioxidants, and the like, and mixtures thereof. These additional components can be included in the packaging solution in an amount effective to impart or provide a beneficial or desired property to the packaging solution. For example, such additional components can be included in the packaging solution in an amount similar to the amount of such components used in other, for example, conventional contact lens care products.

[0125] Suitable sequestering agents include, for example, disodium ethylenediaminetetraacetate, alkali metal hexametaphosphates, citric acid, sodium citrate, and the like, and mixtures thereof.

[0126] Suitable viscosity imparting agents include, for example, hydroxyethyl cellulose, hydroxymethyl cellulose, polyvinylpyrrolidone, polyvinyl alcohol, and the like, and mixtures thereof.

[0127] Suitable antioxidants include, for example, sodium metabisulfite, sodium thiosulfate, N-acetylcysteine, butylated hydroxyanisole, butylated hydroxytoluene, and mixtures thereof.

[0128] The method of packaging and storing a biomedical device such as a contact lens according to the present invention comprises at least packaging the biomedical device immersed in the aqueous packaging solution described above. The method may comprise immersing the biomedical device in the aqueous packaging solution immediately after the manufacture of the contact lens and before delivery to the customer / wearer. Alternatively, packaging and storage in the packaging solution may occur at an intermediate point before delivery to the final customer (wearer), but after the lens is manufactured and shipped in a dry state, where the dry lens is hydrated by immersing the lens in the packaging solution. Thus, the package for delivery to the customer may comprise a sealed container containing one or more unused contact lenses immersed in the aqueous packaging solution according to the present invention.

[0129] In one exemplary embodiment, the steps of providing the packaging system for an ophthalmic device of the present invention include (1) molding a biomedical device in a mold comprising at least a first and a second mold part, (2) hydrating and washing the biomedical device in a container comprising at least one of the mold parts, (3) introducing a packaging solution having one or more crosslinked polymer networks into the container in which the biomedical device is supported, and (4) sealing the container. In one embodiment, the method also includes a step of sterilizing the contents of the container. Sterilization can be performed before sealing the container or, most conveniently, after sealing, by any suitable method known in the art, such as heat sterilization by autoclaving the sealed container at a temperature of about 120° C. or higher, or sterilization by other known techniques, such as UV, beta or gamma radiation, or sterile filtration.

[0130] In another exemplary embodiment, the glycophospholipid polymers and / or cross-linked glycophospholipid polymer networks of the present invention may be in a gel formulation. As will be readily understood by those skilled in the art of formulation, a gel is a semi-solid suspension type system. Thus, in one embodiment, a gel formulation may include one or more of the glycophospholipid polymers and / or cross-linked glycophospholipid polymer networks of the present invention and one or more gel formers. A gel former for use herein may be any gelling agent typically used in the art for semi-solid gel formulations. As used herein, the term "gelling agent" is intended to mean a compound used to make a liquid vehicle into a jelly-like vehicle. Exemplary gelling agents include, by way of example and not limitation, synthetic macromolecules, cellulose derivatives (e.g., carboxymethylcellulose and hydroxypropylmethylcellulose), and natural gums (e.g., tragacanth). Synthetic macromolecules include carbomers (e.g., carbomer 910, 934, 934P, 940, 941, and 1342), which are high molecular weight water-soluble polymers of acrylic acid crosslinked with allyl ethers of sucrose and / or pentaerythritol. The viscosity of the carbomers varies depending on the polymer composition. The gelling agent can be selected from any of the synthetic or semi-synthetic polymeric materials, polyacrylate copolymers, cellulose derivatives, and polymethylvinylether / maleic anhydride copolymers. Various grades of Carbopol can be used in the present invention, such as Carbopol 934, 940, 941, 974, 980, 981, 1342, 5984, ETD2020, ETD2050, and Ultrez 10 (available from Noveon of Cleveland, Ohio). The present invention preferably includes Carbopol 980 as a gelling agent. Carbopol is a carbomer. Generally, carbomers are synthetic high molecular weight polymers of acrylic acid crosslinked with either allyl sucrose or allyl ethers of pentaerythritol.

[0131] The gelling mechanism relies on neutralization of the carboxylic acid moieties to form soluble salts. The polymer is hydrophilic and produces a foamable, transparent gel when neutralized. Carbomer gels have good thermal stability in that the gel viscosity and yield values ​​are essentially temperature independent. Carbomer gels have optimal rheological properties for topical products. The inherent pseudoplastic flow allows for immediate recovery of viscosity when shearing ceases, and the high yield values ​​and rapid break down make them ideal for dispensing. In the pharmaceutical formulations of the present invention, Carbomer gels are used as suspending or thickening agents. Aqueous solutions of Carbopol are inherently acidic due to the presence of free carboxylic acid residues. Neutralization of the solution causes the polymer to crosslink and gelatinize to form a viscous monolithic structure of the desired viscosity. The amount of gelling agent can vary widely, typically ranging from about 0.1% to about 10% w / w.

[0132] The gel composition can be incorporated into a wound dressing (e.g., bandage, adhesive dressing, transdermal patch). Generally, in these embodiments, the gel composition is embedded in a puff, gauze, fleece, gel, powder, sponge, or other material associated with the second layer to form the wound dressing. Absorption enhancers can also be used to increase the flux of the composition across the skin, particularly the therapeutic protein within the composition. The rate of such flux can be controlled by providing a rate-controlling membrane or by dispersing the therapeutic protein in a polymer matrix or gel.

[0133] In exemplary embodiments, the second layer of the wound dressing can be an elastomeric layer, a vapor permeable film, a waterproof film, a woven or nonwoven fabric, a mesh, etc. The composition comprising the layer and the second layer can be joined using any suitable method (e.g., application of an adhesive, such as a pressure sensitive adhesive, a hot melt adhesive, a curable adhesive, etc.; application of heat or pressure, as in lamination; physical attachment by stitching, use of studs, other fasteners, etc.).

[0134] The wound dressing may include an adhesive for attachment to skin or other tissue. Any adhesive suitable for forming a bond with skin or other tissue may be used, although in certain embodiments, a pressure-sensitive adhesive is used. Generally, a pressure-sensitive adhesive is defined as an adhesive that adheres to a substrate upon application of light pressure but leaves little or no residue when removed. Pressure-sensitive adhesives include solvent in solution adhesives, hot melt adhesives, water-based emulsion adhesives, calenderable adhesives, and radiation curable adhesives.

[0135] The most commonly used elastomers for pressure sensitive adhesives include natural rubber, styrene-butadiene latex, polyisobutylene, butyl rubber, acrylic, and silicone. In certain embodiments, acrylic polymer or silicone-based pressure sensitive adhesives may be used. Acrylic polymers often have low levels of allergenicity, are cleanly removable from the skin, have low odor, and exhibit low rates of mechanical and chemical irritation. Medical grade silicone pressure sensitive adhesives may be selected for their biocompatibility.

[0136] Factors influencing the suitability of a pressure-sensitive adhesive for use in certain embodiment wound dressings include the absence of skin-irritating components, sufficient adhesive strength so that the adhesive can be cleanly removed from the skin, the ability to accommodate skin movement without undue mechanical skin irritation, and good resistance to body fluids. EXAMPLES

[0137] The following examples are provided to enable one of ordinary skill in the art to practice the invention, are illustrative only, and are not to be construed as limiting the scope of the invention, as defined in the claims.

[0138] Example 1 Preparation of glycophospholipid polymers of hyaluronic acid (HA) and phosphorylcholine according to general reaction scheme 1 [ka] [wherein n is 100]

[0139] To a 100 mL round bottom flask equipped with a magnetic stirrer was added 60 mL of water (reverse osmosis) and 3.00 g of HA (7.44 mmol based on disaccharide unit), as well as 1.00 g (4.2 mmol) of ethanaminium, 2·[[hydroxy-2-oxiranylmethoxy]phosphinyl)oxy)-N,N,N·trimethyl, inner salt prepared according to the method described in Example 11 of J.Org.Chemistry, 2002, 67194-199, the contents of which are incorporated herein by reference. The solution was then stirred for 15 hours to ensure complete dissolution of the material, resulting in a clear solution with a pH of approximately 7. The pH of the solution was adjusted to 8.09 with 0.25 g of a 10 wt.% solution of sodium hydroxide. After 4.5 hours the pH was 8.82, but after 7 hours it had risen to 9.07. The reaction mixture was stirred for an additional 15 hours, allowing the pH to rise to 9.6. The reaction mixture was then poured into 900 mL of ethanol to give a precipitate, which was filtered. The solid was washed with 3×100 mL of ethanol and dried under high vacuum for 24 hours to give 2.8 g (85% yield) of a white solid.

[0140] Example 2 Preparation of crosslinked polymer networks of HA and glyceryl phosphorylcholine using 1,4-butanediol diglycidyl ether (BDDE) according to general reaction scheme 2 [ka]

[0141] To a 100 mL round bottom flask equipped with a magnetic stirrer, 60 mL of water (reverse osmosis), 3.00 g of HA (7.44 mmol based on disaccharide units), and 3.00 g (11.7 mmol) of glyceryl phosphorylcholine (purchased from Lipoid) were added. The solution was then stirred for 15 hours to ensure complete dissolution of the material, resulting in a clear solution with a pH of 6.65. To this solution was added 1.2 mL of BDDE (6.25 mmol). After 15 minutes of stirring, the pH of the slightly cloudy solution was adjusted to 8.5 with 0.2 g of a 10 wt.% solution of sodium hydroxide. After 24 hours, the reaction mixture was then poured into 900 mL of ethanol to obtain a precipitate and filtered. The solid was washed with 3×100 mL of ethanol and dried under high vacuum for 24 hours to obtain 4.6 g (77% yield) of a white solid. NMR incorporation of the internal methylene group of bound BDDE to the methyl group of the acetamide indicated 2.90 mol % BDDE functionalization.

[0142] Example 3 Preparation of crosslinked polymer networks of HA and hydroxyethyl phosphorylcholine using BDDE according to general reaction scheme 3 [ka]

[0143] In a 100 mL round bottom flask equipped with a magnetic stirrer, 60 mL of water (reverse osmosis), 3.00 g of HA (7.44 mmol based on disaccharide unit), and 3.00 g (13.1 mmol) of hydroxyethyl phosphorylcholine (purchased from Shanghai Chemhere Co., Ltd.) were added. The solution was then stirred for 15 hours to ensure complete dissolution of the material, resulting in a clear solution with a pH of 6.65. To this solution was added 1.2 mL of BDDE (6.25 mmol). After stirring for 15 minutes, the pH of the slightly cloudy solution was adjusted to 8.5 with 0.2 g of a 10 wt.% solution of sodium hydroxide. After 24 hours, the reaction mixture was then poured into 900 mL of ethanol to obtain a precipitate and filtered. The solid was washed with 3×100 mL of ethanol and dried under high vacuum for 24 hours to obtain a white solid of 4.9 g (77% yield). NMR incorporation of the internal methylene group of bound BDDE to the methyl group of the acetamide indicated 3.2 mol % BDDE functionalization.

[0144] Example 4 Preparation of crosslinked polymer networks of HA and ethanaminium, 2-[[[(carboxymethoxy)hydroxyphosphinyl]oxy]-N,N,N-trimethyl inner salt with adipic dihydrazide (ADH) according to general reaction scheme 4: [ka]

[0145] To a 50 mL Erlenmeyer flask equipped with a stir bar was added 31.9 mL of (reverse osmosis) water and 1.50 g of HA (3.72 mmol based on disaccharide units). To another Erlenmeyer flask equipped with a stir bar was added 31.9 mL of (reverse osmosis) water and 0.170 g (0.706 mmol) of ethanaminium, 2·[[hydroxy-2-oxiranylmethoxy]phosphinyl)oxy]-N,N,N·trimethyl inner salt. Both solutions were stirred for 15 hours to ensure complete dissolution of the material. To each solution was added 0.075 g (0.389 mmol) of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in 0.5 mL of (reverse osmosis) water. Each vessel was rinsed with 0.5 mL of (reverse osmosis) water. The solutions were stirred for 5 minutes and then added to a 100 mL round bottom flask equipped with a stir bar. The flasks were rinsed with 2 mL of (reverse osmosis) water each. To this solution was added 0.062 g (0.353 mmol) of ADH in 0.5 ml of (reverse osmosis) water. The pH was adjusted from 7.08 to 4.54 with 6.08 g of 0.1 N HCl. After 40 min, the pH was adjusted from 6.15 to 4.53 with 3.49 g of 0.1 N HCl. After 6 h, the pH was 4.65, and after 24 h, the pH was adjusted from 4.65 to 7.36 with 0.425 g of 10 wt.% sodium hydroxide. The solution was dialyzed against 100 mM sodium chloride using a molecular weight cut-off (MWCO) of 3500 in PBS buffer (1.0 mM), changing the dialysis bath every 3 h. A total of 6 changes were made. The third and fourth changes were made with 50 mM NaCl and 1 mM PBS buffer. The final two exchanges were with (reverse osmosis) water only. The solution was lyophilized for 3 days to give 2.70 g of a fluffy white solid (78% yield). NMR incorporation of the internal methylene group of the bound ADH to the methyl group of the acetamide indicated 4.75 mol % ADH functionalization.

[0146] Example 5 The packaging solution is made by mixing the following components in the respective amounts shown in Table 1. [Table 1]

[0147] Example 6 The packaging solution is made by mixing the following components in the respective amounts shown in Table 2. [Table 2]

[0148] Example 7 The packaging solution is made by mixing the following components in the respective amounts shown in Table 3. [Table 3]

[0149] Example 8 The packaging solution is made by mixing the following components in the respective amounts shown in Table 4. [Table 4]

[0150] Example 9 The packaging solution is made by mixing the following components in the respective amounts shown in Table 5. [Table 5]

[0151] Example 10 The packaging solution is made by mixing the following components in the respective amounts shown in Table 6. [Table 6]

[0152] Example 11 The packaging solution is made by mixing the following components in the respective amounts shown in Table 7. [Table 7]

[0153] Example 12 The packaging solution is made by mixing the following components in the respective amounts shown in Table 8. [Table 8]

[0154] Example 13 The packaging solution is made by mixing the following components in the respective amounts shown in Table 9. [Table 9]

[0155] Example 14 The packaging solution is made by mixing the following components in the respective amounts shown in Table 10. [Table 10]

[0156] Example 15 The packaging solution is made by mixing the following components in the respective amounts shown in Table 11. [Table 11]

[0157] Autoclave degradation studies showed no statistically significant changes in pH, viscosity and osmolality after three autoclave cycles, as shown in Table 12 below. [Table 12]

[0158] Example 16 Contact lenses made from Balafilcon A are cast and processed under standard manufacturing procedures. Balafilcon A is a copolymer composed of 3-[tris(trimethylsiloxy)silyl]propyl vinylcarbamate, N-vinyl-2-pyrrolidone (NVP), 1,3-bis[4-vinyloxycarbonyloxy]but-1-yl]polydimethylsiloxane, and N-vinyloxycarbonylalanine. All Balafilcon A lenses are air plasma treated prior to exposure to a crosslinked polymer network.

[0159] To coat with the crosslinked polymer network of Example 1, each lens is placed into a polypropylene blister package containing 3.8 mL of a 100 or 250 ppm (w / v) solution of the crosslinked polymer network dissolved in an appropriate buffer system, e.g., phosphate buffered saline system (PBS), borate buffered saline (BBS), with or without 300 ppm EDTA, The blister package is sealed with a foil lidstock and autoclaved at 121° C. for 30 minutes.

[0160] Example 17 Contact lenses made from Balafilcon A are cast and processed under standard manufacturing procedures. Balafilcon A is a copolymer composed of 3-[tris(trimethylsiloxy)silyl]propyl vinylcarbamate, N-vinyl-2-pyrrolidone (NVP), 1,3-bis[4-vinyloxycarbonyloxy]but-1-yl]polydimethylsiloxane, and N-vinyloxycarbonylalanine. All Balafilcon A lenses are air plasma treated prior to exposure to a crosslinked polymer network.

[0161] To coat with the crosslinked polymer network of Example 2, each lens is placed into a polypropylene blister package containing 3.8 mL of a 100 or 250 ppm (w / v) solution of the crosslinked polymer network dissolved in an appropriate buffer system, e.g., PBS, BBS, with or without 300 ppm EDTA, The blister package is sealed with a foil lidstock and autoclaved at 121° C. for 30 minutes.

[0162] It will be understood that various modifications may be made to the embodiments disclosed herein. As such, the above description should not be construed as limiting, but merely as exemplifications of preferred embodiments. For example, the functions described and implemented above as the best mode for carrying out the invention are for illustrative purposes only. Other arrangements and methods may be implemented by those skilled in the art without departing from the scope and spirit of the invention. Moreover, those skilled in the art will envision other modifications within the scope and spirit of the features and advantages appended hereto.

Claims

1. 1. A glycophospholipid polymer comprising the reaction product of one or more glycosaminoglycans having one or more reactive functional groups, one or more phospholipids having one or more reactive functional groups, and one or more first crosslinkers, The one or more crosslinkers include a bifunctional or polyfunctional crosslinker comprising two or more functional groups, a first functional group of the two or more functional groups of the bifunctional or polyfunctional crosslinker is an epoxide functional group, a bond between the epoxide functional group of the bifunctional or polyfunctional crosslinker and at least one of the one or more reactive functional groups of the one or more glycosaminoglycans is an ether bond, and a second functional group of the two or more functional groups of the bifunctional or polyfunctional crosslinker forms a bond with at least one of the one or more reactive functional groups of the one or more phospholipids.

2. The glycophospholipid polymer according to claim 1, wherein the one or more glycosaminoglycans are selected from the group consisting of chondroitin, chondroitin sulfate, dermatan, dermatan sulfate, heparin, heparan sulfate, hyaluronan, hyaluronic acid, or salts thereof, and the one or more phospholipids are selected from the group consisting of phosphorylcholine-containing phospholipids, phosphorylhistidine-containing phospholipids, phosphorylproline-containing phospholipids, phosphorylserine-containing phospholipids, α-phosphatidylethanolamine, α-phosphatidyl-L-serine, α-phosphatidylinositol, α-phosphatidic acid, α-phosphatidyl-DL-glycerol, α-lysophosphatidylcholine, sphingomyelin, and cardiolipin.

3. The glycophospholipid polymer of claim 1 or 2, wherein the one or more phospholipids comprise a phosphorylcholine-containing phospholipid comprising a zwitterionic group represented by the following structure: 【Chemistry 1】 wherein n is an integer from 1 to 5; R′, R″, and R′″ are each independently selected from C １ ~C ８ Alkyl group, C １ ~C ８ a hydroxyalkyl group, or a heteroatom-containing group.

4. The glycophospholipid polymer according to any one of claims 1 to 3, wherein the one or more glycosaminoglycans are hyaluronic acid or a salt thereof, and the one or more phospholipids include a phosphorylcholine-containing phospholipid.

5. The glycophospholipid polymer according to any one of claims 1 to 4, wherein the one or more additional glycosaminoglycans are crosslinked with a reaction product with one or more second crosslinkers.

6. A biomedical device having a coating on a surface thereof, said coating comprising one or more of the glycophospholipid polymers according to any one of claims 1 to 5.

7. The biomedical device of claim 6 , wherein the biomedical device is an ophthalmic lens.

8. 10. A packaging system for storage of ophthalmic devices, comprising a sealed container housing one or more unused ophthalmic devices immersed in an aqueous packaging solution comprising one or more of the glycophospholipid polymers according to any one of claims 1 to 5, wherein the aqueous packaging solution has an osmolality of at least 200 mOsm / kg and a pH of 6 to 9, and is sterile.

9. 1. A method for preparing a package containing a storable sterile ophthalmic device, comprising: (a) immersing an ophthalmic device in an aqueous packaging solution comprising one or more of the glycophospholipid polymers according to any one of claims 1 to 5, said aqueous packaging solution having an osmolality of at least 200 mOsm / kg and a pH in the range of 6 to 9; (b) packaging the aqueous packaging solution and the ophthalmic device in a manner that prevents contamination of the device with microorganisms; (c) sterilizing the packaged solution and the ophthalmic device; and A method comprising:

10. An aqueous ophthalmic composition comprising one or more of the glycophospholipid polymers according to any one of claims 1 to 5, and having an osmolality in the range of 200 mOsmol / kg to 400 mOsmol / kg.

11. 11. The aqueous ophthalmic composition of claim 10, in the form of an eye care or contact lens care product selected from the group consisting of eye drops, rewetting drops, contact lens storage solutions, contact lens cleaning solutions, and all-purpose contact lens solutions.

12. A gel composition for promoting wound healing, comprising one or more of the glycophospholipid polymers according to any one of claims 1 to 5.

13. A wound dressing comprising the gel composition of claim 12.

Images